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Abstract 
Tachykinins (TKs), including substance P (SP), neurokinin A (NKA) and neurokinin 
B (NKB) are neuropeptides released from sensory nerves. They had been shown to 
have proinflammatory actions in many inflammatory diseases. In this project, the 
relationship between SP and the pathology of arthritis was investigated using a rat 
monoarthritis model induced by Freund's complete adjuvant (FCA). The 
effectiveness of TK receptor antagonists in suppressing arthritis was examined. In 
addition, the anti-arthritic efficacies of the TK receptor antagonists combined with a 
steroid were tested. 
Two species of rats, the inbred Lewis rats and the outbred Sprague-Dawley rats were 
compared for use as a monoarthritis model. Lewis rats were found to produce smaller 
vascular changes, and joint swelling compared with those observed in 
Sprague-Dawley rats. Hence, Sprague Dawley rats were chosen for use as the 
monoarthritis model. This monoarthritis model resembles the human rheumatoid 
arthritis disease under histological examinations, the FCA-injected knee (test) 
showed immune cell accumulation, synovial tissue proliferation, cartilage 
degradation and bone erosion during the 28 days of assessment, and in this period 
there was little or no sign of these symptoms in the contralateral saline-injected 
control knee. 
Unilateral intra-articular injection of SP into the test knee of the monoarthritic animal 
augmented Evans blue extravasation and vasodilatation bilaterally. In addition, 
oedema, immune cell accumulation, synovial tissue proliferation and cartilage 
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degradation were also observed in the contralateral saline-injected knee. Therefore, 
SP was confirmed to be an important mediator in the development of the present 
arthritis model and it plays a pivotal role in the spreading of the disease to 
contralateral joints. 
The anti-arthritic efficacies of several tachykinin receptor antagonists were examined. 
NKi receptor antagonists were found to be most effective and suppressed all the 
arthritic symptoms. On the other hand, the NK2 receptor antagonist (SR48968) was 
less efficacious and suppressed a few of the symptoms such as Evans blue 
extravasation, joint swelling and synovial tissue proliferation. The NK3 receptor 
antagonist (SRI 42801) was the least effective and it reduced Evans blue 
extravasation only. Therefore, NKi receptor antagonists were found to have the 
highest potential for the development of novel anti-arthritic agents. 
The final part of this project examined the anti-arthritic efficacies of combined 
treatment of tachykinin receptor antagonists with a steroid (dexamethasone). 
Co-administration of the NKi receptor antagonist SRI 40333 with dexamethasone 
produced greater suppression on immune cell infiltration and synovial tissue 
proliferation than those produced by either of these agents on their own. However, 
the combined treatment of an NK2 receptor antagonist (SR48968) with 
dexamethasone produced no further inhibition. These findings consolidated the view 
that tachykinin NKi receptors play a more significant role than the other tachykinin 
receptor types in the arthritis processes in the present model. 
In summary, this study has established a chronic monoarthritis model using outbred 
Sprague-Dawley rats. SP is an important mediator in the development of the arthritis 
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as it was shown to exacerbate and accelerate the onset of the arthritis, and promoted 
the spread of the disease to the contralateral joint. These actions of SP were mediated 
by the activation of tachykinin NKi receptors, and hence, inhibitors ofNKi receptors 
were shown to possess useful anti-arthritic properties. Moreover, the combined 
treatment of an NKi receptor antagonist with a steroid produced greater inhibition of 
the arthritis symptoms than either of these agents used alone. Therefore, this 
combination treatment may represent a novel anti-arthritic therapy endowed with less 
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1.1 Normal joint  
1.11 Biology of the joint 
Bones are too rigid to bend without causing damage. Fortunately, the skeletal system 
consists of many separate bones, most of them held together at joints by flexible 
connective tissues. All the movement that change the position of the body occur at 
joints. Joints are a part of the skeleton that enable movement to occur between two or 
more bones. Based on the types of motions that they accommodate, the vertebrate 
joints are classified into 3 main categories: immovable joints (e.g. structure of skull), 
slightly movable joints (e.g. intervertebral disc) and movable joints (e.g. the knee). 
The last category, also known as diarthrodial (/.e. synovial joints), are freely movable. 
1.12 Structure of synovial joints 
The structure of a synovial joint (i.e. the knee) is shown in Figure 1.1. The joint 
space, called the synovial cavity, develops between growing bone islands in the 7-9 
weeks in human foetus, it is bound by the synovium lined capsule. There is synovial 
fluid in the synovial cavity which provide nutrients for the avascular articular 
cartilage. The articular cartilage covers the surfaces of the articulating bones. 
Between two bones, there is another cartilageous tissue called the meniscus. Along 
the meniscus and the capsule, there are many bursae, e.g. fat pad that reduce friction 
during movement. Each of the components of synovial joints is described below. 
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Figure 1.1 Anatomy of a knee joint 
The structure of a knee joint includes the capsules that are lined with synovial 
membrane (synovial lining). Beneath this layer are vascular adipose, and fibrous 
tissues that support the synoviocytes and allow the sac to be appropriately loose for a 
certain range of motion during movement (Modified from Simkin P. A., Introduction 
of human joint. Biology of joint, 23, 1993). 
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1.13 Components of the mature synovial joint  
1.131 Articular cartilage 
Cartilage is a semi-rigid form of supporting tissue. Different proportions of collagen 
and elastic fibres give rise to different types of cartilage: hyaline cartilage, 
fibrocartilage and elastic cartilage. In synovial joint, the articular cartilage is a 
hyaline cartilage, which covers the bone end. Together with synovial fluid, they 
cushion the bone ends during joint movement and compression, and provide very 
low friction surfaces for joint movement. The thickness of the cartilage is less than 
5mm in human joints and it varies from joint to joint and even at different sites 
within the same joint (Meachim, 1971). There are no blood vessels penetrating the 
articular cartilage; the chondrocytes of this avascular structure obtain nutrients and 
oxygen and removal of metabolites via the synovial lining layers and synovial fluids. 
Cartilage formation commences with the differentiation of mesenchymal cells to 
form chondroblasts. Subsequent mitotic divisions lead chondroblasts to grow and 
synthesize ground substances. The divisions give rise to clusters of mature 
chondrocytes. 
Articular cartilage consists of water, collagen, complex ground substances e.g. 




More than 70% of the cartilage is water. The highly charged aggrecan participates in 
flux of water through the cartilage via effective charge currents when the cartilage is 
compressed and then unloaded. The elastic nature of cartilage is caused by the 
reversible stacking ability of the aggrecan and collagen array to reversibly absorb 
water. When inflammation occurs, the control of influx of water is lost, and the 
amount of water in the joint is increased (Martin et al., 2000; Muir, 1995). Oedema 
of the cartilage results. 
1.1312 Cartilage matrix 
Cartilage matrix includes collagen and ground substances. Collagen, mainly type II 
and type IX provide stability of the fibril framework in cartilage. The absence of type 
IX collagen in homozygous mouse model is associated with articular cartilage 
degeneration similar to human osteoarthritis (Fassler et al,, 1994). In addition，some 
mutations in the type II collagen gene may be responsible for a hereditary form of 
osteoarthritis (Eyre et al., 1991). 
Ground substances such as proteoglycans and glycosaminoglycan are found in 
articular cartilage. They are one of the supporting tissues in the cartilage and act as 
the ground for the exchange of nutritions for the chondrocytes. In return, ground 
substances are synthesized by the chondrocytes. The balance of synthesis and 
degradation of the ground substances are influenced by cytokines, proteases, and 
their inhibitors secreted by chondrocytes, synoviocytes, and inflammatory cells. 
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1.1313 Chondrocyte 
Chondrocytes are scattered within individual lacunae of the cartilage. They occupy 
about 2% of the total cartilage volume, and are responsible for the maintenance of a 
normal cartilage matrix. Chondrocytes are the source of all the matrix components, 
such as collagen II, IX and XI and proteoglycans, as well as degradation enzymes e.g. 
matrix metalloproteases. During chronic inflammation, chondrocytes proliferate, and 
the production of degradation enzymes is increased. 
1.132 Synovium 
Synovium encloses all parts of the joint except for the articular cartilage and the 
meniscal cartilage. Being derived from mesenchymal tissue, it has no epithelial cells 
and there is no formal basement membrane underlying the synovial lining cells; they 
are separated from each other by chemical barriers such as membrane peptidase 
(Mapp, 1995). The synovium is highly vascularized (Haywood & Walsh, 2001; Sick 
& Ring, 1976) and innervated (Pozza et al” 2000; Rozovskaya & Yankovskaya, 1975; 
Tanaka et al., 1977). It can be divided into the synovial lining (intima) and the joint 
capsule. 
Synovial lining is only four cell layers deep. Its depth varies from one site to another 
but is usually around 25 i^m in human (Simkin, 1993). It has mainly two functions: 
synthesis of protein, (e.g. glycoproteins, enzymes, growth factors) and phagocytosis 
(endocytosis). There are two cell types (Type A and Type B cells) in this intimal 
layer. Owing to their resemblance to macrophages, type A cells are called 
macrophage-like cells; they have lysosomes for ingestion of cell debris. Type B cells 
are called fibroblast-like cells, or synoviocytes, because of their prominent rough 
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endoplasmic reticulum and Golgi apparatus that have a similar appearance to those 
of the fibroblast, and they have secretory properties. Differentiation of the lining cells 
is governed by the activating stimuli present in their environment, rather than being 
predetermined to a restricted population during embryogenesis. If debris is present, 
type A cells are numerous. If growth factors or inflammatory cytokines are present, 
fibroblast-like B cells proliferate and produce proteases and matrix components 
(Kawakami et al, 1998). 
The capsule is a dense connective tissue lined with synovial lining cells, and forms a 
sleeve around the articular bones to which it is attached. The main function of the 
capsule is to seal the joint to keep the lubricating synovial fluid in position. It is the 
most innervated part in the joint; the fast conducting, myelinated A-fibres are 
important for proprioception and detection of joint movement (Mackie & Rowe, 
1998); whereas the slow-conducting, unmyelinated C-fibres transmit diffuse pain 
sensation and regulate capsule microvascular functions. These innervations are 
important in protecting the joint and its associated ligaments by reflex control of the 
appropriate musculature. The innervation patterns vary in different diseases of the 
joint (Schmidt, 1996). 
1.1321 Synovium vasculature 
Normal synovium is richly vascularised, providing the high blood flow required for 
the exchange of solutes and gases, not only for the synovium itself but also for the 
needs of the avascular articular cartilage. In addition, the synovial vasculature is 
essential for the production of synovial fluids. It also behaves as an endocrine organ 
generating factors that regulate synoviocyte functions, and it is a gateway to recruit 
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inflammatory cells in times of need. Furthermore, it regulates intra-articular 
temperature. 
The synovial vasculature can be divided on morphological and functional grounds 
into arterioles, capillaries, and venules. In normal physiological state, the joint 
vasculature is highly organized and different tissues have varying degrees of 
vascularisation. The endothelial gaps in the capillaries are sufficiently small to 
provide exchange of water and small solute proteins, but plasma proteins are retained 
within the blood vessels. However, during inflammation, there is increased vascular 
turnover and the growth of subchondral blood vessels in articular cartilage are 
observed in arthritic patients (Haywood & Walsh, 2001). Moreover, "large pores" in 
the form of wide intercellular gaps can be found in venules (postcapillary vessels of 
� 1 0 jam) of inflamed synovia that would allow exudation of large plasma protein 
molecules into the interstitial tissues (Bignold & Lykke, 1975; Schumacher, 1973). 
1.1322 Synovial blood flow 
The regulation of synovial blood flow depends on the perivascular nerves, the 
endothelium and also the physiological conditions of the joints. The perivascular 
nerves can be divided into sympathetic nerves and sensory nerves. Each of these 
nerves contains many vasoactive neurotransmitters. In sympathetic nerves, 
adenosine 5'-triphosphate (ATP) and 5-hydroxytryptamine (5-HT) act as the main 
vasodilators, whereas, noradrenaline (NA) and neuropeptide Y (NPY) act as 
vasoconstrictors (Bumstock & Ralevic, 1994). In sensory nerves, substance P (SP), 
calcitonin gene-related peptide (CGRP), somatostatin and cholecystokinin can � 
modulate the vascular tone (Pernow, 1985). Perivascular nerves regulate synovial 
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blood flow by endothelial cells. Endothelial cells form a continuous monolayer at the 
innermost surface of all blood vessels, its situation is unique to sense and respond to 
changes in the circulation. Endothelium controls blood flow by producing 
vasodilatation and constriction. Upon stimulation by vasoactive substances such as 
arachidonic acid, SP, NKA, 5-HT, bradykinin, histamine, ACh, endothelium would 
respond by releasing nitric oxide (NO), or prostaglandins in some vessels, that would 
contribute to smooth muscle relaxation. Endothelial cells can also mediate 
vasoconstriction via endothelium derived constricting factors (EDCF), which are 
diffusible factors produced in response to various chemical stimuli such as NA and 
thrombin. EDCF could be metabolites of arachidonic acid, endothelin or endothelin 
itself. The mechanisms of how EDCF contribute to vasoconstriction are still under 
investigation. 
Besides nerve and endothelium-dependent control, synovium blood flow could be 
affected by changes in the joint physiology; factors such as high intra-articular 
pressure, joint motion, immobilization, synovectomy and intra-articular temperature 
can all affect the synovial blood flow (Levick, 1990). 
1.133 Synovial fluid 
Synovial fluid is the provider of nourishment in the synovial joint; it also acts as 
lubricant in the cavity and as a sink for solute and cells from the phagocytosis of 
synovial lining cells and the macromolecules of the lymphatic system. In the normal 
situation, this viscous fluid cannot be collected in a measurable volume. In response 
to inflammation, the increased synovial vascularity and permeability produced more 
synovial fluid, and more large-size proteins, such as fibrinogen, macroglobulin and 
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immunoglobulin can be found in the fluid (Chatham et al, 1993; Hansson et al, 
1985; Lu-Steffes et al., 1982; Melikhova & Smimov, 1980) 
1.134 Bone 
Bone is the hardest tissue in the body. It is an essential component in the joint for 
providing stability and it contained bone marrow for new blood formation. Adult 
bones can be divided into two types: compact and trabecular bone. Compact bone 
forms the shafts of long bones and much of the exterior surface of flat bones. It is the 
hardest frame for the whole skeleton. Trabecular bone is found in the extremeties and 
marrow cavities of long bones, the vertebrae and centres of flat bones. It appears as a 
mesh of bone strands (1mm thick in human), although much less solid than compact 
bone, the arrangement of the trabeculae bone forms an ideal weight bearing structure. 
The major components of bones are not static, but undergo continuous remodeling. 
Dead Cells are replaced, and collagens and minerals are eroded and are formed 
throughout the healthy adult life. This remodeling process involvs reabsorption and 
deposition of the bone structure at an equilibrium so that the volume and shape of the 
bones remain more or less constant. However, in inflammation, the remodeling 
process is disturbed (Simkin, 1993). 
There are three types of bone cells, namely osteoblasts, osteocytes and osteoclasts. 
Osteoblasts are immature cells. They are differentiated to carry out the function of 
bone formation. On the completion of their bone-forming activity, most osteoblasts 
revert to quiescent undifferentiated cells and rest among the heterogenous cell 
population. In the process of maturation, when osteoblasts are trapped in the matrix 
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they become mature osteocytes, and reside in the lacunae of the bone. The last 
category, osteoclasts are the bone destroyers. They are seen in small clusters on bone 
surfaces that are undergoing erosion or resorption. They are important in bone 
remodeling. However, during inflammation, osteoclast number is greatly increased 
(Simkin, 1993). 
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1.2 Pathological processes of arthritis 
Joints are frequently affected by inflammatory and degenerative disorders. The major 
consequences of articular disorders are functional impairment of the joint, 
hyperalgesia and/or pain in the joint region. The inflammatory response is stimulated 
by the release and activation of a plethora of mediators that include the cytokines, 
eicosanoids, complement and kinin systems, histamine, 5-HT, and neuropeptides (for 
review see Scott et al., 1994). If the agent causing tissue damage is antigenic then 
there will also be a specific immune response, both humoral and cellular, which 
interacts with the general inflammatory response. This cellular response is the 
predominant factor of chronic inflammation. However, some inflammatory reactions 
of long duration are the result of persistent inflammation involving the non-specific 
process of congestion, exudation and phagocyte migration. Acute inflammation may 
also be an initiating factor in chronic inflammatory disease such as rheumatoid 
arthritis (RA), where the necessary genetic susceptibility factors exist to allow the 
perpetuation of the disease. 
The pathological processes involved in the development of chronic arthritis are 
complex, but may be divided into 3 steps for simplicity. The first step is activation of 
the immune response, the second step is proliferation of synovial tissue and the last 
step is cartilage and bone degradation. Each of these steps will be explained briefly. 
1.21 Activation of immune cells in arthritis 
An inflammatory reaction is a host defense mechanism for the elimination of 
invading microorganism, inactivation of toxins, and to prepare the tissue or organ for 
healing processes and repairs. However, the inflammatory reactions may be 
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detrimental if it is persistent. Arthritis is an example of a disease caused by persistent 
activation of the immune inflammatory reactions in joints. 
Eosinophils and neutrophils are the first inflammatory cells to arrive at the site of 
injury or infection. They limit the spread of the disease by phagocytosing the bacteria 
and cellular debris. In arthritis, neutrophils are more prominent and are found in 
abundance in synovial fluids of arthritis patients (De Clerck et al., 1995). Monocytes 
appear at the site of injury after neutrophils and eosinophils. After arrival, the 
monocytes mature to macrophages. Initially, they contribute to the phagocytosis 
process, but in the chronic state, they produce cytokines and growth factors that 
perpetuate the inflammatory responses (Kinne et al., 2000). 
Mast cells are found throughout the synovial lesion (Bromley et al., 1984; Woolley 
& Tetlow, 2000). They contain many granules and lysosomes for enhancement of 
inflammatory responses e.g. vascular permeability, vasodilatation. In addition, mast 
cells have a role in activating the destructive processes, e.g. at the paimus-cartilage 
junction (Woolley & Tetlow, 2000). They are activated by T cells, monocytes, 
macrophages, neutrophils and neuropeptides. Mast cells release mediators such as 
histamine and tryptase that stimulate chondrocytes to produce prostaglandins and 
metalloproteases (Taylor & Woolley, 1987; Taylor et al., 1985), which enhance 
degradation of the cartilage. Mast cells also influence the transformation of 
synoviocytes (Gadher & Woolley, 1987). 
T lymphocytes and B lymphocytes are important in the initiation and maintenance of 
synovitis. They produce cytokines and immunoglobulins that directly worsen the 
joint lesion as well as causing activation of other inflammatory cells (Kim & Berek, 
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2000; Weyand & Goronzy, 1999; Weyand et al., 2000). 
1.22 Synovial proliferation 
Synovial tissue proliferation is characterized by hyperplasia of synovial lining cells, 
angiogenesis and infiltration of mononuclear cells. Eventually, there is pannus 
invasion and cartilage degradation. The disease involved complex interactions 
between immune cells and fibroblasts that lead to the release of cytokines, 
inflammatory neuropeptides and growth factors. They all exert a synergistic 
mitogenic effect on synovial tissue fibroblasts. The altered rates of proliferation and 
apoptosis of the synovial cells result in hyperplasia of synovial tissues and ultimately 
lead to destruction of the joint. 
1.221 Synovial lining cell activation 
The synovial lining cells are activated early in the development of arthritis. The 
potential for proliferation is much higher for fibroblast-like type-B cells than type-A 
(macrophage-like) cells (Iwanaga et al, 2000). The activated lining cells are 
transformed, resembling those of cancer cells capable of invading local connective 
tissues, but lining cells do not undergo malignancy and are unable to metastasize 
(Michael & Alisa, 2000). Furthermore, the activated lining cells can synthesize many 
enzymes for collagen synthesis (Smith et al., 1998). The new collagen and matrix 
glycoprotein are laid down in the capsule and the capsule becomes thickened (Smith 
et al., 1998; Martel-Pelletier et al., 1999). In addition, lysosome is highly expressed 
in macrophage-like cells in the intimal layers (Schwenke & Richter, 1989)，and about 
60% of lining cells stain positively for metalloprotease (Konttinen et al., 2000; 
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Yamanaka et al., 2000). The activated lining cells can autonomously and 
continuously express cytokines, enzymes and matrix, which lead to further synovial 
proliferation and subsequent unregulated cartilage and bone degradation described 
below (Dooley et al., 1996). 
1.222 Pannus invasion 
Pannus is the invasion results from the massive growth of synovial tissues that 
invade the edge of the cartilage. The attractive force for pannus invasion is mediated 
by adhesion molecules e.g. very late antigen-4 (VLA-3), VLA-4, and fibronectin, 
expressions of which are increased in the pannus and the cartilage surface in arthritic 
joints (Edwards, 2000). In addition, the majority of arthritis patients have 
immunoglobulins and complements in the superficial layers of their articular 
cartilages (Cooke et al., 1975). These immuno-complex deposits activate 
macrophages near the synovial lining layer, and the gradient of cytokines generated 
by these macrophages impels the synovial lining and dendritic cells towards the 
cartilage (Konttinen et al., 1998). 
1.23 Cartilage and bone degradation 
Bone and cartilage can be damaged by multiple factors in arthritis. The dominant 
factors are the proteases released from neutrophils, chondrocytes, synovial cells, and 
oxygen-derived free radicals (ODFR). After the cartilage is degraded, activities of 
osteoclasts are able to erode the underlying subchondral bones. Details of cartilage 
and bone destruction are described in the following sections. 
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1.231 First step in destruction: Depletion of proteoglycan (GAG) 
The articular cartilage is a terminally differentiated tissue. Once degraded, it is 
difficult to regenerate effectively. The initial cartilage damage is caused by depletion 
of negatively charged-proteoglycan (GAG) in the cartilage. The initiating factors are 
cytokines e.g. IL-1 and TNFa released from synovial cells that induce release of 
degradation enzymes e.g. stromelysin from synovial cells and chondrocytes. These 
enzymes degrade the proteoglycan molecules to smaller fractions that diffuse into the 
synovial fluid. Water will then replace the GAGs and changes the texture and 
stiffness of the cartilage, once GAGs is lost, the joint becomes flimsy and deformable 
and cannot rebound from compressions. Cartilage taken early in the course of the 
disease shows normal gross appearance of the tissue but a marked depletion of 
proteoglycan on histological examination (Malemud, 1991), and degraded GAG can 
be found in synovial fluids of arthritic patients (Lohmander et al., 1998). 
1.232 Second steps: Collagen denatured bv immune cells and its components 
Once proteoglycan is lost, the cartilage becomes exposed. The degradation of 
proteoglycans and collagens is facilitated by immunoglobulins (Chatham et al., 
1993), which are found in abundance on cartilage surfaces of arthritis patients 
(Terato et al., 1996). Neutrophils from synovial fluids and anti-type II collagen 
antibodies would adhere to the exposed cartilage (Jasin et al., 1993; Jasin & Taurog, 
1991). The adhered neutrophils release metalloproteases, and the anti-type II 
collagen antibodies bind to epitopes exposed in denatured collagen and this would 
further degrade the collagen (Jasin & Taurog, 1991). When the collagen 
microskeleton of the cartilage is lost, repair by regeneration is impossible. 
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Under stimulation, some of the macrophages and monocytes would differentiate to 
osteoclasts (Chang et al., 1992). They reach the bone by the invasive pannus. When 
stimulated by inflammatory mediators, the osteoclasts pumps protons into the 
extracellular pocket to decrease the pH. The low pH dissolves the minerals, and the 
metalloproteases (MMPs) and acid proteases then further degrade the matrix 
glycoproteins and collagen in the bone (Pozza et al, 2000; Rozovskaya & 
Yankovskaya, 1975; Tanaka et al., 1977). Macrophages isolated from synovium of 
rheumatoid arthritis patients are capable of producing extensive erosion of bone 
(Sakai et al, 1998; Cooke et al, 1975). 
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1.3 Tachykinins (TKs) 
1.31 History 
Tachykinins are a family of peptides that share the common C-terminal sequence 
Phe-Xaa-Gly-Leu-Met-NHi in which X represents Phe or Val in mammalian forms. 
The C-terminal is essential for biological activities. The name tachykinin is derived 
from their rapid initiation of smooth muscle contraction compared with the 
slow-acting bradykinin (Pemow, 1985). In 1931, von Euler and Gaddum discovered 
the first TK substance P (SP) in extracts of equine intestine. Fifty years later, two 
other TKs, neurokinin A (NKA) and neurokinin B (NKB) were discovered in extract 
of porcine spinal cord. TKs have also been found in non-mammalian tissue extracts 
such as those from posterior salivary glands of the Mediteranean octopus (Weld et al, 
1994) and those from the skin of African Rhacophorid frogs (Erspamer & Cd, 1970). 
1.32 Synthesis, storage and release of TKs 
TKs are encoded by two major genes, preprotachykinin PPT-I and PPT-II. 
Alternative splicing during transcription of the PPT-I gene yields three large PPT 
mRNA; 丫 a - , p-PPT. Upon translation, these different mRNAs produce three 
different precursors that, when processed, yield differing combinations of tachykinin 
peptides. 丫-PPT-I encodes one SP, a-PPT-I and P-PPT each encodes one SP plus one 
NKA molecules while PPT-II is the main source for NKB. 
TKs are produced within the neuronal cell body, packed into vesicles and axonally 
transported to the terminal endings for final enzymatic processing (Donnerer et cd., 
1993; Maggi et al., 1987). They are stored in large granular synaptic vesicles in 
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sensory nerve endings (Floor & Leeman, 1985) until arrival of appropriate stimulus 
triggering their release. 
SP, NKA, calcitonin gene-related pephide (CGRP)， somatostatin, 
thyrotrophin-releasing hormone and 5-hydroxytryptamine (5-HT) co-exist in many 
sensory nerve terminals. They may be co-released or selectively released depending 
on the frequency of stimulation. SP is released only under high frequency stimulation 
(Tsunoo et al., 1982) and its release involves L-and N-type C^^ channels (Holz et aL, 
1988). 
1.33 Tachykinin receptors 
TKs exert their biological effects via interaction with three pharmacologically 
well-defined receptors; the neurokinin 1 (NK!), NK2 and NK3 receptors. The cloning 
and sequencing of three distinct genes from mammalian sources have confirmed their 
existence. This classification is based on the different affinities of endogenous TKs 
for the receptors such that SP, NKA and NKB preferentially bind to NKi, NK2 and 
NK3 receptors respectively. However, the receptor selectivity of these TKs is 
relatively poor, and it is possible that their actions are mediated by their less 
preferred receptor subtypes. In respect to the functional sequence of the tachykinins, 
these receptors recognize the C-terminal sequence of TK molecules, but some 
evidences indicate that SP action is occasionally mediated via its N-terminal 
sequence (Paegelow et al., 1989). 
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1.331 Characterization of NKi receptor 
The NKi receptor is a 407 amino acid residue receptor protein. It is defined as the 
mediator of the biological activities encoded by the C-terminal sequence of TKs for 
which SP is a more potent agonist than NKA and NKB. There are species variations 
of NKi receptors, revealed by different affinities of various NKi agonists and 
antagonists in different species (Saria, 1999). NKi receptors are widely distributed in 
the central nervous system (CNS) and the peripheral nervous system (PNS) of 
various species. In the brain, NKi receptors are found in regions such as the nucleus 
accumbens, the hippocampus, the lateral nucleus of the hypothalamus, the habenula, 
the nucleus of the tractus solitarius, the raphe nuclei and the medullar oblongata 
(Patacchini & Maggi, 1995). NKi receptors are involved in migraine headache, 
emesis and some psychiatric diseases. The use of NKi receptor antagonists to treat 
emesis and depression had been tested in clinical trials with satisfactory results 
(Diemunsch et al., 1999; Reid et al., 2000). In the spinal cord, NKi receptors are 
found in the dorsal horn and the intermediolateral nucleus of the thoracic spinal cord 
and some nuclei in the ventral horns. The main involvement ofNKi receptors in the 
spinal cord is in pain transmission (Aicher et al., 2000). In the PNS, NKi receptors 
play a role in the physiology and pathophysiology of the respiratory system, 
digestive system, skin, joint, and the immune system. 
1.332 Characterization ofNKi receptor 
The NKi receptor is defined as the mediator of the biological actions encoded by the 
C-terminal sequence of TKs, for which NKA is a more potent agonist than SP and 
NKB. NKi receptors are widely distributed in the peripheral nervous system and 
especially in smooth muscles of the respiratory, gastrointestinal and urinary tracts. In 
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CNS, NK2 receptors are found in the thalamic nuclei, in discrete layers of the frontal 
cortex and in the hypothalamus (Bensaid et al., 2001). There is heterogeneity among 
NK2 receptors; the first NK2 receptor is a 384 amino acid residue isolated from 
bovine stomach. Human trachea and jejunum NK2 receptors have 390 amino acids. 
NK2 receptors are involved in the pathogenesis of asthma, inflammation, cough and 
pain (Joos et al., 2000; Laird et al, 2001). 
1.333 Characterization ofNKi receptor 
NK3 receptor is defined as the mediator of those biological actions, encoded by 
C-terminal sequence of TKs, for which NKB is a more potent agonist than NKA and 
SP. Among the three TK receptors, NK3 showed greatest variation between different 
species (Couture et al., 2000). Human and rat NK3 receptors showed only 88% 
homology with 7 variant positions. The pharmacological actions of NK3 receptors 
are not well understood, because of the poor expression of NK3 receptor in the 
peripheral nervous system. However, NK3 receptors are abundantly expressed in the 
CNS and spinal cord (Guo et aL, 1997; Langlois et al., 2001), especially in the 
human and rat hypothalamus (Flynn, 1999; Koutcherov et al., 2000). NK3 receptors 
have been implicated in the regulation of blood pressure (Cellier et aL, 1997). In 
addition, NK3 receptors are suspected to be involved in reducing salt intake by 
modulating the oral-stimulating property of salt taste as intraventricular injection of 
NK3 agonists increased the taste intensity to salt (Flynn, 1999). 
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1.34 Effector systems ofTKs 
All three TK receptors belong to the superfamily of rhodopsin-like 
G-protein-coupled receptors with 7 transmembrane-spanning segments. Tachykinin 
receptors in different types of tissue use different effector systems, but the major one 
is stimulation of phosphatidylinositol breakdown. In rat salivary gland, rat brain and 
guinea pig tracheal smooth muscle, tachykinin receptors are coupled to the 
pertussis-toxin-insensitive Gq proteins which are linked to physphoinositide 
metabolism (Grandordy et al, 1988). In some cell types e.g. cultured neuroblastoma 
cells and dog thyroid gland, tachykinin receptor activation is coupled to adenylyl 
cyclase, via Gs proteins (Narumi & Maki, 1978; Yamashita et al., 1983). However, in 
rat pituitary gland, tachykinin receptors are coupled to adenylyl cyclase inhibition via 
Gi proteins (Laniyonu et al., 1988). 
135 Terminaion of TK signals 
1.351 Enzymatic breakdown 
The magnitude and duration of action of tachykinins are regulated by 
angiotensin-converting enzymes (ACE) and the neutral endopeptidase. ACE 
hydrolyzes C-terminal bonds of SP in respiratory tract (Yokosawa et al, 1983). In 
epithelial layer of guinea pig small intestine, SP degradation is mediated by neutral 
endopeptidase 24.11 (NEP) (Defea et al., 2000), dipeptidylaminopeptidase (DPAP) 
(Horsthemke et al., 1984)，and also by prolylendopeptidase (Scharpe & De Meester, 
2001). NKA and NKB are good substrates for NEP. NKA is also degraded by 
dipeptidylaminopeptidase IV (Nau et al., 1986). Differential degradation of SP, NKA 
and NKB, by NEP and ACE in particular, may influence tachykinin potencies on 
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target tissues. 
1.352 Receptor desensitization 
Besides enzyme degradation, cell signals are attenuated by receptor desensitization. 
After agonist activation, the receptor undergoes phosphorylation that would uncouple 
the activated receptor from its G-protein. Two kinases; serine/threonine protein 
kinase and protein kinase A mediate tachykinin receptor desensitization. The C-tail 
and third intracellular loop of the TK receptor contains many serine and threonine 
residues for phosphorylation of the receptor, after which the receptor is bound by 
P-arrestin, the signaling pathways is then terminated (McConalogue et al., 1998). 
1.353 Receptor endocytosis 
Agonist-induced endocytosis of TK receptors is another form of receptor 
desensitization. By fluorescent and histochemical staining techniques, the binding of 
SP to its receptors was found to cause internalization of the receptors in transfected 
epithelial cells, enteric neurones, and endothelial cells (Grady et al, 1997; 
McConalogue et al., 1998; Honor et al., 1999). The internalized receptors (bound 
with SP) would then be coated with clathrin and form vesicle. Acidification of the 
vesicle dissociates SP with the receptors. SP would then be degraded by lysosomes 
and the receptors are recycled back to the plasma membrane. 
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1.36 Tachykinin receptor antagonists 
1.361 Selective NKi receptor antagonist 
Various synthetic ligands have been developed which are selective antagonists for the 
NKi receptors. The first peptide-based antagonists claimed to possess some NKi 
receptor selectivity was the cyclic peptide L668169 (Williams et al., 1988). A major 
breakthrough came with the introduction of the quinuclidine derivative CP96345, the 
first example of a nonpeptide TK receptor antagonist (Desai et al., 1992; Snider et al, 
1991). In some species, especially in rat and mice, the affinity of CP96345 for the 
NKi receptor is low (in the \xM range). Several nonspecific effects of CP96345 e.g. 
depression of smooth muscle contractility to various stimulants, blockade of neuronal 
excitability/transmitter release, reduction in blood pressure and cardiac performance 
in vivo) have been described (Lecci, 1994; Wang, 1992; Wang et al, 1991). These 
nonspecific effects are linked to the interaction of CP96345 with various types of 
membrane channels, including L and N-type calcium channels (Schmid et aL, 1992; 
Guard et al., 110) and voltage dependent sodium channels (Caesar et al., 1993). 
A follower of CP96345 which reportedly overcomes some of these drawbacks is 
CP99994 (McLean et al., 1993). The reported affinity of CP99994 for NKi receptor 
in the human IM9 cell line (pKi 9.6) is comparable to that of CP96345 (pKi 9.6) but 
its affinity for [^H]desmethoxyverapamil binding to rat heart membrane (pICso 5.52) 
is about 100-fold lower than that of CP96345 (pICso 7.56) (McLean et al., 1993). 
Soon after the discovery of CP96345, a number of other nonpeptide NKi receptor 
antagonists were described, such as RP67580 (Garret et al., 1991), SR140333 
(Edmond-Alt et al., 1993)，RPR100893 (Fardin et al., 1994), CGP94832 (Hauser et 
al., 1994) and L732138, a tryptophan-based nonpeptide antagonist (MacLeod et al., 
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1993). 
RP67580 is an important compound since it has been instrumental in unravelling the 
species-dependent variation in the pharmacology of the NK! receptor, being a 
significantly more potent blocker at rat and mouse than guinea-pig NKi receptor. 
RP67580 is especially useful for studies aiming to assess the physiological roles of 
NKi receptor in rat and mouse species (Garret et aL, 1991). SR140333 is one of the 
most potent NKi receptor antagonists available at present. SR140333 has been 
reported to possess sub-nM affinity for rat, guinea-pig, pig and human NKi receptors 
in binding assays e.g. Ki= 0.019 nM in the human IM9 cell line (Edmond-Alt et al., 
1993). Interestingly, this antagonist does not discriminate between rat and human 
NKi receptors (Edmond-Alt et al., 1993; Jensen et al., 1994). 
1.362 Selective NKi receptor antagonists 
A number of peptide-based ligands have been developed, with selective antagonist 
activity at the NK2 receptor. The first example of a selective NK2 receptor antagonist 
was the cyclic hexapeptide L659877 (McKnight et al, 1991; Williams et al., 1988). 
This compound possessed 100-1000-fold greater affinity for the NK2 receptor in rat 
vas deferens (pKs 8.0) than for NKi and NK3 receptors. Dion and co-workers (1990) 
introduced a linear derivative of L659877, which is a selective antagonist for the 
hamster type of NK2 receptor (Maggi et al, 1990). Efforts have been made to obtain 
more potent and selective analogues of L659877 through the development of cyclic 
hexapeptide derivatives containing pseudopeptide bonds such as MDL29913 (Van 
Giersbergen et al., 1991), MEN 10573 and MEN 10612 (Maggi et al., 1993; Quartara 
et aL, 1994): the latter compounds possessed improved potency and selectivity for 
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NKi receptors, as compared to L659877，and also longer duration of action in vivo. 
The major breakthrough in NK2 receptor pharmacology was the introduction of the 
first nonpeptide NK2 receptor antagonist, SR48968 (Edmond-Alt et al., 1992). This 
compound is endowed with high affinity for NK2 receptors and marked selectivity vs 
NKi and NK3 receptors. The second example of a highly potent nonpeptide NK2 
receptor antagonist is GR159897. It possesses high affinity (p^i 9.5) for human 
ileum NK2 receptor expressed in CHO cells and comparable high affinity for NK2 
receptor in rat colon membranes (p幻 10) (Ball et al., 1994). It is also highly potent in 
blocking NK2 receptors in vivo after intravenous or oral administration (Ball et al, 
1994). 
1.363 Selective NKi receptor antagonists 
The heptapeptide [Trp?, pAla^]NKA(4-10) has been described as a selective NK3 
receptor antagonist in the rat portal vein but it also acts as an agonist at other 
receptors (Drapeau et al., 1990) and its value seem very limited. Afterwards, the 
peptide GR138676 has been described as a quite potent NK3 receptor antagonist (pKb 
8.24 in rat portal vein) although it is equally potent in blocking NKi receptors (pKb 
8.26 in U373 MG cells). 
In 1994, Emond-Alt and colleagues introduced a novel potent non-peptide NK3 
receptor antagonist: SRI 42801. This antagonist possesses nM affinity for guinea-pig 
NK3 receptor and is about 2 log unit more potent in blocking NK3-mediated 
contraction of guinea-pig ileum than in rat portal vein. A similar selectivity was also 
reported between NK3 (guinea-pig) and NK2 or NKi receptors (Edmond-Alt et al., 
1994). The non-peptide derivative PD157672 likewise possesses high binding 
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affinity for human NK3 receptor (IC50 16nM in transfected CHO cells) and 
guinea-pig NK3 receptor and large selectivity over NKi and NK2 receptors (IC50 > 
5000nM) (Boden et al., 1994). 
A summary on the tachykinin receptor types and their respective antagonists is given 
in Table 1.3. 
26 
Table 1.3，Classification of tachykinin receptors 
Currently accepted NKi NK2 NIC] 
name  
Structural 407 amino acid (aa) 398 aa (human) 465 aa (human) 
information (human)  
~ ~ P r e f e r r e d S P NKA NKB 
endogenous 
peptide  
Subtype selective L668169 L659877 [Trp?, 
peptide antagonist MEN10573 PAla^]NKA(4-10) 
MEN10612 GR138676 
MDL29913 
Subtype selective CP96345 SR48968 SR142801 







1.4 Roles of tachykinins in arthritis 
1.41 Correlation between tachykinins and joint inflammation 
Accumulating evidence suggests that tachykinins, in particular SP, contained in 
sensory C fibres play an important role in joint inflammation. Histological findings 
showed that nerves innervating the knee joint contain immunoreactive SP, which is 
considered the marker of sensory fibres (ElfVin et al., 1998; Mapp et al., 1990). 
Many of SP immunoreative nerves are found in the perivascular area, with some 
extending through the intima almost as far as the synovial surface (Elfvin et al., 1998; 
Mapp et al, 1990). There are also evidences that showed SP receptors are present in 
the vascular endothelium of human synovial tissues (Walsh et al., 1992). 
SP immunoreactivity is present after adjuvant-induced arthritis in synovia of feline 
knee joints (Marshall et al., 1997). In proliferating synovia of rats with 
adjuvant-induced arthritis, the amount of nerve is reduced and SP-containing nerves 
are found only at the junction of the bone and synovial membrane (Konttinen et al., 
1990). Similar findings are reported in the synovia of patients with arthritis (Mapp et 
al., 1990; Pereira DA Silva & Carmo-fonseca, 1990). These findings may indicate an 
increased released of SP in diseased joints, thus reducing the stores in the nerves to 
levels below those detectable by immunohistochemistry. In accordance with this 
view, elevated level of SP are detected in the synovial fluid from patient with RA 
(Devillier et al., 1986; Marabini et al., 1991). 
The accumulated evidence from pharmacological studies also supports the idea that 
SP contributes to inflammatory processes in joints. Thus, tachykinin antagonist 
inhibits plasma protein extravasation in the cat knee joint induced by antidromic 
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stimulation of the articular nerve C-fibres (Ferrell & Russell, 1986). Perfusion of a 
joint with SP enhances cartilage and bone damage in adjuvant-arthritis of the rat 
(Levine et al., 1984). Acute joint inflammation in the rat knee joint induced by 
carrageenan was also shown to have a substantial neurogenic component, which is 
mediated by SP and perhaps other tachykinins (Lam & Ferrell, 1989). 
Administration of tachykinin is effective in causing plasma extravasation and 
vasodilatation in the rat knee joint (Lam & Ferrell, 1993; Lam & Ferrell, 1991). 
Moreover, SP can induce collagenase release from rheumatoid synoviocytes and 
stimulates their proliferation through specific receptor-mediated mechanism (Lotz et 
al., 1987). This added support to the notion that local release of SP from peripheral 
afferents contributes to the development and severity of rheumatoid arthritis. 
Pain is one of the symptoms of inflammatory diseases, especially in arthritis. 
Administration of SP or other TKs in rodents elicits pain responses, such as 
scratching, biting, licking of forelimbs, similar to those induced by peripherally 
applied noxious stimuli (Laneuville et al., 1988). There is good correlation between 
the amount of SP-immunoreactivity and the nociceptive nature of the cells. SP is 
found more abundantly in nociceptive neurones than in non-nociceptive neurones in 
the cat spinal cord (Kai-Kai, 1989). In addition, NKi and NK3 receptor mRNA levels 
are increased in rat spinal cord in noxious conditions (Palmer et al., 1999). There is 
an upregulation of NKi receptors at discrete sites of the spinal cord after surgery 
(CrouUr al, 1995). 
NKi receptor antagonists e.g. CP96345 and MK801 produced inhibition on the 
nociceptive reflex in rats (Yamamoto et al., 1993). CP96345 and GR 82334 also 
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reduced the exaggerated response to innocuous pressure in inflamed joints (Santos & 
Calixto, 1997). Unfortunately, the majority of clinical trials showed negative results 
withNKi receptor antagonists as analgesic agents (Coudore-Civiale et al, 1998). 
Further evidence implicating SP involvement in joint inflammation includes studies 
that showed increased expression of SP in peripheral nerve, dorsal root ganglia and 
spinal cord (L4-L5) of rat with adjuvant-induced polyarthritis (Colpaert et al., 1983; 
Lembeck et al., 1981) and the release of SP-like immunoreactivity from central 
endings of primary afferents in the spinal cord (Schaible et al., 1990) 
1.42 Roles of tachykinins in immune cell activation 
NKi receptors are present on the endothelial cells of capillaries. Activation of these 
receptors by SP causes rapid mobilization of adhesion molecules {e.g. P selectin) for 
polymorphonuclear cells to the endothelial cell surface, presumably by increasing the 
intracellular Ca^ "^  concentration (Homma et al., 2001; Kraan et al., 2001). SP has 
also been shown to exert direct chemotactic actions on neutrophils and eosinophils 
(Eglezos et al., 1991; Lotz et al., 1988). 
Besides neutrophils and eosinophils, SP has been shown to exhibit proinflammatory 
actions in macrophages, including activation of arachidonic acid metabolism, 
chemotaxis and oxidative burst (Chancellor-Freeland et al., 1995; McGillis et al., 
1990). Berman and colleagues (1996) demonstrated that SP has a stimulatory role in 
causing release or accumulation of interleukin-1 (IL-1) from murine peritoneal 
macrophages. Similarly, SP has been shown to increase the release of IL-1, IL-6 and 
tumor necrosis factor-alpha (TNFa) from human monocytes (Lotz et al., 1988; 
30 
Rameshwar et al., 1993). 
Rat mast cell TNF-a mRNA is selectively upregulated by SP in a dose-dependent 
manner (Ansel et al., 1993)，and SP can evoke degranuation of mast cells causing 
release of mediators (Cocchiara et al., 1999). Peptidergic nerve fibres and mast cells 
are associated anatomically in several tissues including human larynx and marine 
skin (Domeij et al., 1996; Botchkarev et al, 1997). 
SP binds to murine T lymphocytes and modulates their functions. It promotes T cell 
adhesion to endothelial cells by up-regulating adhesion molecule expression 
(Vishwanath & Mukherjee，1996). It also stimulates human T cells DNA synthesis 
(McGillis et al., 1987), and enhances the proliferation of lymphocytes from spleen 
and mesenteric lymph nodes (Stanisz et al., 1986). SP and NKA act as a co-signal to 
increase the expression of specific cytokines e.g. IL-2, IL-4 and IL-10 and their 
secretion by T cells, which act in an antocrine maimer to stimulate the activation and 
production of T cells (Levite, 1998; Eglezos et al., 1991). In addition, SP enhances 
the maturation and differentiation of spleenic B cells in rats (Blum et al., 1996; 
Pascual et al., 1991) and increases the synthesis of immunoglobulin (Braun et al., 
1999). NKA stimulates proliferation of thymocytes in vitro (Soder & Hellstrom, 
1989). 
1.43 Role of tachykinins in synovial proliferation 
The expression of NKi receptor mRNA is upregulated in synovial tissues of 
rheumatoid arthritis patients, which correspond with serum C-reactive protein levels, 
and the disease progression (Partsch et al., 1991; Sakai et al., 1998). SP has been 
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shown to increase the expression of vascular intercellular adhesion molecule-1 
(VCAM-1) and fibroblast-like synoviocytes (Dijkgraaf et al., 1997). SP and 
capsaicin also dose-dependently induce collagenase production in synoviocytes that 
causes cartilage degradation (Lambert et al., 1998; Hecker-Kia et al., 1997). 
Moreover, SP and NKi receptor agonist have been shown to stimulate angiogenesis 
in a rat sponge model and in a reverse manner, NKi receptor antagonists were found 
to inhibit angiogenesis (Fan et al, 1993). 
1.44 Roles of tachykinins in cartilage degradation 
SP is suspected to be a mediator for initiation of cartilage degradation. This is 
because of SP injected intra-articularly into inflamed rat knee joints produced 
bilateral proteoglycan loss which can be inhibited by NKi antagonists (Decaris et al, 
1999). In addition, depletion of sensory neurones by capsaicin reduces the number of 
osteoclast and bone resorption (Adam et al., 2000). On the other hand, SP had been 
shown to enhance osteoclast production and SP antagonists reverse this enhancement 
in rabbit (Mori et al, 1999). 
32 
1.5 Animal models of arthritis 
Animal disease models are valuable for the study of conditions that resemble human 
disease without the use of human subjects. Human rheumatoid arthritis (RA) is 
characterized by a tissue-specific inflammatory attack affecting diarthrodial joints. 
Although systemic manifestations can be prominent, the predominant inflammatory 
attack is directed towards peripheral joints. In RA, chronicity is an essential 
characteristic. The disease course may proceed with identifiable relapse, and there is 
usually steady progression of joint destruction. Therefore, there are two main criteria 
for the establishment of an animal model of arthritis; one is tissue specificity and the 
other is chronicity. 
Dogs, monkeys, rabbits, guinea-pigs, rats and mice have been used as arthritis 
models (Colpaert et aL, 2001; Hart et al., 1998; Hood et al., 2001; McLay et al., 
2001; Oilier et al., 2001; Pelletier et al., 2000), and a variety of arthritis models have 
been developed. These can be divided into instability model, immobilization-induced 
model, and noxious agents-induced models. They each have their own advantages 
and disadvantages. 
1.51 Instability model 
Ligament sectioning has been used to induce arthritis in dogs. It results in synovitis, 
fibrillation and erosion of the cartilage surface, and changes of proteoglycan content 
in the cartilage. However, the site of the sectioning, breed, age and weight of the 
animal would affect the onset and degree of cartilage degradation (Lozoya & Flores, 
2000). 
33 
1.52 Immobilization model 
Cartilage change can be induced by disuse of the joint. When dogs are placed in a 
cage with 90° flexion of the hip and the knee and immobilized against the trunk, 
cartilage loss is induced. The thickness of the cartilage is decreased with change in 
the cartilage contents. These changes are reversible (Meyer-Carrive & Ghosh, 1992). 
1.53 Noxious agent -induced model 
Several infectious or noxious agents may invade and persist in joints, thereby causing 
arthritis. Inflammation may be caused directly by the infections or the noxious agent, 
but may be also the result of aberrant inflammatory responses of the host. A brief 
review on the noxious agent induced arthritisis presented below and in Table 1.5. 
1.531 Collagen- induced erosive arthritis (CIA) 
Type II collagen is highly arthritogenic in Lewis rats. The CIA model is produced by 
intradermal injection of type II collagen in Incomplete Freund's adjuvant (IFA), 
followed by a booster injection on day 7 in the animal. Erosive polyarthritis typically 
develops 10 to 14 days after primary immunization. Autoreative T cells and B cells， 
which produce antibodies to Type II collagen, play a critical role in disease 
progression. Similar to RA, females tend to be more susceptible than males, and the 
arthritic rats also produce rheumatoid factors (Enokida et al., 2001). In addition, in 
this model, persistent joint inflammation, synovial hyperplasia and immune cell 
infiltration were found. Also, most therapies are effective. 
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1.532 Cartilage oligometric matrix protein (COMPVinduced arthritis 
Injection with native and denatured rat COMP in Imcomplete Freund's Adjuvant 
(IFA) induces severe arthritis in rats. The arthritic joints develop symptoms that 
resemble RA，including symmetrical joint involvement and controlled by the gene 
involved in arthritis. However, this model dose not result in permanent destruction of 
the joints (Carlsen et al., 1998; Hansson et al., 1999). 
1.533 Oil-induced arthritis 
Oil-induced arthritis only works in specific strains of rats. The joint inflammation 
produced is much less severe than that observed in other rat arthritis models. Single 
injection of IFA subcutaneously produced arthritis around day 14 with symmetrical 
joint involvement, immune cell infiltration and bone erosion. Most importantly, they 
are regulated by the genes that are involved in arthritis (Jansson et al., 2000; Kleinau 
et al, 1995;Lorentzen et al, 1998). 
1.534 Streptococcal cell wall-induced arthritis 
This is produced by a single intraperitoneal injection of an aqueous suspension of 
cell wall peptidoglycan-polysaccharide fragments from streptococci and several 
other types of bacteria into susceptible rat strains. The onset of the disease is within 
24 hours (Houri & O'Sullivan, 1995; Wilder et al., 1989). It has most of the 
histological features similar to that of human RA, also female are more susceptible 
than that of male. However, this model does not have rheumatoid factors. 
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1.535 Adiuvant-induced arthritis (AIA-induced) 
Intradermal injection of heat-killed mycobacteria at the base of the rat's tail results in 
destructive arthritis within 14 days. The disease progresses rapidly，and increased 
synthesis of TNFa, IL-1 and IL-6 are detected as early as day 4 after adjuvant 
injection. Granunocyte and CD4+ cells play a major role in the disease, which 
resemble the immunogenicity of human arthritis. The signs of AIA are also similar to 
the human disease, including symmetrical joint involvement, (sometimes 
polyarthritis), synovial hyperplasia, inflammatory cell infiltration, bone erosion. 
Most of the RA therapies are also effective in AIA model. However, AIA is a 
systemic disease that involves not only joint, but also the gastrointestinal tract, the 
skin, and the eyes (Schleyerbach & Wedde, 1984). 
1.536 Pristane-induced arthritis (PIA) 
This form of arthritis is not easily inducible in species other than rats and mice. The 
induction of PIA requires repeated intraperitoneal injections of pristine that triggers 
an inflammatory disease with a late and insidious onset (Potter & Wax, 1981). This 
model resembles the human disease in that it is T-cell dependent, MHC-associated 
and involved multiple joints and synovial hyperplasia. However, pristane has the 
capacity to induce tumour after intraperitoneal injections (Potter & Wax, 1981). 
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Table 1.5 Summary of arthritis models induced by noxious agents 
Model Similarities to human disease Differences from 
human disease 
Collagen-induced Persistent joint inflammation Anti-collagen 
arthritis Synovial hyperplasia response not 
Inflammatory cell infiltration present in cases of 
Marginal erosions RA 
Presence of rheumatoid factor 
Anti-collagen antibodies 
Genetically regulated by MHC and 
non-MHC genes 
Responsive to most therapies effective 
inRA 
Greater susceptible to female 
COMP-induced Symmetrical joint involvement No permanent 
arthritis Peripheral joints affected destruction of joints 
Immune response to proteins in the 
cartilage 
Genetically regulated by MHC and 
non-MHC genes 
Oil-induced Symmetrical j oint involvement 1. Absence of 
arthritis Peripheral joints affected Rheumatoid 
Inflammatory cell infiltration factors 
Bone erosion 2. Only specific 
- I  
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I Regulated by MHC and non-MHC strain of rats are 
genes affected 
3. Less severe 
Streptococcal cell Symmetrical joint involvement Absence of 
wall-induced Persistent and relapsing joint Rheumatoid factors 
arthritis inflammation 
Synovial hyperplasia 
Inflammatory cell infiltration 
Bone erosion 
Greater susceptibility in females 
Adjuvant-induced Symmetrical joints affected Gastrointestinal, 
arthritis Persistent joint inflammation genitourinary tract, 
Synovial hyperplasia skin affected 
Inflammatory cell infiltration 
Marginal bone erosions 
Genetically regulated by MHC and 
non-MHC genes 
Responsive to most therapies effective 
inRA 
Pristane-induced Symmetrical joint involvement 1. Mild to 
arthritis Synovial hyperplasia moderately 




1.6 Current anti-arthritic therapies 
As discussed in the early sections, there are multiple factors and mediators involved 
in the pathogenesis of arthritis. It is therefore unlikely that the use of any single agent 
can completely halt the disease progression. Variations in, age, and stages of the 
diseases, all affect the outcome of their responses to treatment. Therefore, although 
there are many different therapies against arthritis but there is no best drug for all 
patients. In the following, some of the most commonly used anti-arthritic drugs are 
discussed. 
1.61 Non steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are among the most widely prescribed drugs. There are over 100 million 
prescriptions of NSAIDs filled annually in the USA alone. The first synthesized 
NSAID was acetylsalicylic acid e.g. aspirin (Laurence and Bennett, 1987). 
Subsequently, several other distinct classes of NSAIDs have been developed, notably 
naproxen and indomethacin. NSAIDs have been used for many years in rheumatoid 
arthritis without evidence that they can actually modify the course of disease. They 
are regarded as drugs that are useful for suppressing the symptoms, but not the 
immunopathogenic mechanisms that drive rheumatoid synovitis. Most of the 
NSAIDs have three basic effects: antipyretic, analgesic, and anti-inflammatory 
effects. 
The general mechanisms of NSAID actions are related to the inhibition of 
arachidonate cyclooxygenase enzymes responsible for the production of 
prostaglandins and thromboxanes. 
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For anti-inflammatory actions, NSAIDs reduce the adherence of leucocytes to 
endothelial cells (PGEi is the chemokine for neutrophils), decrease vascular 
permeability (PGEs and PGI2 are vasodilators that can potentiate plasma exudation), 
and decrease oedema (PGE2 can cause inflammatory swelling in animal model). 
NSAIDs also reduce inflammatory cytokines because they inhibit the activation of 
the transcription factor nuclear factor-Ke, which is essential for transcription of many 
genes involved in the inflammatory processes, such as IL-1, TNFa and cell adhesion 
molecules. 
For analgesic effects, decreasing prostanoid synthesis would greatly reduce the pain 
sensation. This is because PGEs can sensitize peripheral sensory nerve endings 
located at the site of inflammation (Bley et al., 1998). In addition, the 
cyclooxygenase products may act in the spinal cord to facilitate transmission of pain 
responses (Goppelt-Struebe & Beiche, 1997). 
Pyresis occurs when endogenous pyrogens are released from white cells that are 
activated by infection, hypersensitivity, or inflammation. The mechanism of 
antipyretic effect of NSAIDs is mainly due to inhibition of PGE2 production and 
release in the hypothalamus. PGE2 causes the elevation of the set point for 
temperature in the hypothalamus, which is the centre for regulating body 
temperature. 
There are two types of COX enzymes, COX-1 and COX-2. COX-1 enzymes are 
constitutively expressed in lots of tissues, and are involved in maintaining 
homeostasis. COX-2 enzymes are normally present in low levels, but their synthesis 
is upregulated in inflammation, and they are therefore more important for the 
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synthesis of prostanoids involved in inflammation. NSAIDs inhibit the functions of 
both COX-1 and COX-2. Thus, treatment with NSAIDs often cause side-effects as a 
result of inhibition of the constitutive COX-1 enzymes. Their side effects are listed in 
Table 1.61. 
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Table 1.61 Side effects ofNSAIDs 
Systems affected Effects References 
Gastrointestinal Erosive gastritis, Bielecki & Filippini, 1993 
Peptic ulceration 
Blood Antiplatelet, prolonged Tyutyulkova et al, 1984 
bleeding time 




Respiratory Broncho spasm, Tanasescu et al., 2000 
Rhinitis, 
Nasal polyposis 
Uterine Delayed parturition, Simon, 1998 
Dystocia 


















In 1949, a 29-year-old woman was given three injections of 100 mg hydrocortisone. 
She became asymptomatic, and rose from a bed in which she had been immobilized 
for 4 years. This surprising discovery resulted in a Nobel Prize in 1950. The finding 
triggered the widespread use of natural and synthetic adrenocortical hormones for a 
wide variety of inflammatory disease. Glucocorticosteroids (steroid) are now the 
most commonly used group of agents in controlling chronic inflammatory diseases. 
Steroids inhibit the synthesis of inflammatory cytokines such as IL-1, IL-3, IL-4, 
IL-5, IL-6, TNFa and granulocyte-macrophage colony stimulating factor (GM-CSF). 
Also, steroids accelerate the breakdown of mRNA of IL-1, IL-3 and GM-CSF. 
Furthermore, they inhibit the synthesis of certain cytokine receptors, such as IL-2 
receptor (Northrop et al., 1992), and decrease the level of NFkB, a transcription 
factor that activates inflammatory cytokines (Quan et al., 2000). 
Steroids reduce the production of phospholipase A! (PLA2) and cyclooxygenase-2 
gene expression in monocytes. As a result, the synthesis of leukotrienes, 
prostaglandins and platelet-activating factors are reduced. In addition, steroids affect 
neuropeptide metabolism by inducing the synthesis of degradation enzymes such as 
angiotensin converting enzymes and neutral endopeptidases (NEP), that are 
responsible for degradation of bradykinin and tachykinins (Pinto et al., 1999). 
Furthermore, steroids reduce the expression of NK2 receptors in trachea of the cow 
(Katsunuma et al., 1998). However, side effects are common with steroid therapy, 
especially in long-term use. These are summarized in Table 1.62. 
44 
Table 1.62 Side effects of long-term glucocorticoid treatment 
Systems affected Effects References 
Immune system Become vulnerable to Lauerma et al., 1999; 
common and opportunistic Sarlis et al., 2000 
infections 
Skeletal Osteoporosis Lauerma et al., 1999; 
Sarlis et al, 2000 
Gastrointestinal Peptic ulcers Morand, 2000 
Humoral Peripheral insulin resistance Swcnson et al., 1987 
Suppression of growth in 
children Bello & Garrett, 1999 
Prolonged suppression of the 
hypothalamic-pituitary-adrenal Morand, 2000 
axis after drug discontinuation 
Occular Cataract formation in elderly Bello & Garrett, 1999 
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1.63 Second-line treatment 
Second-line drugs are also called disease-modifying antirheumatoid drugs 
(DMARDs). They can reduce the symptoms and signs, and alter the course of the 
disease when given before the joint damage begin. Most of these drugs are relatively 
"slowing acting"; gradual suppression of the signs and symptoms of inflammation 
may not be apparent until months after initiation of therapy with DMARDs. Some 
examples of this group of agents are sulfasalazine, gold salts, D-penicillamine, 
methotrexate and hydroxychloroquine. These are discussed below. 
1.631 Sulfasalazine 
The exact mechanism of action of sulfasalazine is not clearly known, but it can 
scavenge oxygen radicals and inhibit the production of arachidonic acid products. It 
also facilitates accumulation of anti-inflammatory molecules e.g. adenosine in cells. 
Some trials showed that after 16 weeks treatment with sulfasalazine, the serum 
concentration of IgA and IgG are significantly reduced. Sulfasalazine exerts a 
beneficial effect earlier (within 4 weeks after starting the drug) than gold or 
D-penicillamine. It improves joint swelling, tenderness, grip strength and pain score. 
Some studies showed that sulfasalazine reduced intestinal inflammation and blood 
loss inflicted by NSAIDs. Therefore, it is used relatively early in rheumatoid arthritis 
in combination with NSAIDs (Bird, 1995). 
Many patients withdraw from this drug because of nausea and vomiting or even 
abdominal anorexia. Enteric-coated preparation of sulfasalazine is now available, and 
this has reduced the rate of vomiting (Bird, 1995). 
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1.632 Gold salts 
Gold salts include sodium aurothiomalate and auranofin. The beneficial effects of 
these agents are relatively slow; they are normally seen 2 to 4 months after initiation 
of treatments. Therefore, these drugs are often used in combination with faster acting 
drugs like prednisone. Gold salts are usually given by injection, and thus the 
treatment requires visits to the clinic. 
The exact mechanism of gold salts is still under investigation, but it is believed that 
they inhibit activities of lysosomal and other cellular and extracellular enzymes. 
They also inhibit prostaglandin biosynthesis, interfer with complement activation, 
protect from oxidant injury, and inhibit neutrophil phagocytosis and chemotaxis. In 
addition, they inhibit protein kinase C, which is involved in signal transduction in a 
number of inflammatory cell types (Vischer, 1984). 
Gold salts can cause serious side-effects such as thrombocytopenia, proteinuria, 
diarrheoa, nausea and skin rash. Other rare side effects include pulmonary 
hypersensitivity presented as acute respiratory distress, enterocolitis and neurological 
complications resembling encephalopathy (Sagransky & Greenwald, 1980). 
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1.633 D-penicillamine 
D-penicillamine is usually used for patients who fail to respond or cannot tolerate 
hydroxychloroquine, methotrexate, or gold salts, or a combination of these agents, or 
in patients with active vasculitis involving skin or internal organs. 
The main mechanism of D-penicillamine is decreasing immunoglobulin levels 
(Golding et al., 1973) and the concentrations of circulating immune complexes 
(Forster & McConkey, 1986). It has been shown to inhibit neutrophil chemotaxis 
(Chwalinska-Sadowska & Baum, 1976), reduces the rate of collagen deposition in 
synovial proliferation (Moritz, 1975), suppresses human fibroblast proliferation in in 
yitro studies (Gross, 1972; Matsubara & Hirohata, 1988) and inhibits angiogenesis in 
in vivo studies (Ronchetti et al., 1985). 
Some of the side effects of D-penicillamine are similar to gold salts. 
Thrombocytopenia and neutropenia can occur at any time, perhaps as a result of a 
suppressive effect on stem cell maturation (Steen et al, 1986). D-penicillamine has 
been shown to cause taste disturbance due to chelation of zinc within enzymes 
essential for taste (Gutierrez Fuentes et al., 1984). It also causes skin eruption (Lee & 
Sharifi, 1984; Steen et al., 1986). Autoimmune diseases have also been observed in 
some patients e.g. dermatomaositis, systemic lupus erythematosus, pemphigus and 
myasthenia gravis (Suarez-Almazor et al, 2000). These may take over a year to 
recover even after stopping D-penicillamine. 
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1.634 Antimalarials 
Hydroxychloroquine and chloroquine are used for the treatment of malaria. They 
have been shown to cause remission of rheumatoid arthritis but they do not retard the 
progression of bone damage. Their effects are weaker than those of most other 
DMARDs. However, one major advantage of antimalarials is their lack of 
life-threatening toxicity compared to other DMARDs. Therefore, 
hydroxychloroquine and chloroquine are usually used in combination with other 
DMARDs to control the more severe disease (Tmavsky et al., 1993). 
The mechanism of action of chloroquine and hydroxychloroquine remains 
controversial. Most probably, it inhibits of the antigen processing ability of 
macrophages and monocytes, including inhibition of lymphocyte transformation, 
chemotaxis, and IL-1 secretion by monocyte. As a result, the stimulation of 
autoimmune CD4+ T cells is reduced, leading to a down-regulation of autoimmune 
responses (Fox, 1993). 
The range of adverse effects is similar for hydroxychloroquine and chloroquine, but 
hydrochloroquine is reported to have an incidence of adverse effects about half of 
that of chloroquine in the usual doses. Their most common side-effects are listed in 
Table 1.63 
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Table 1.63 Side effects of antimalarial drugs 
Systems affected Effects References 
Gastrointestinal Epigastric discomfort, Fox, 1993 
Nausea 
Dermal Urticaria, Rynes, 1993 
Lichenoid changes, 
Erythema 
Occular Bull's eye retinopathy Rynes, 1993 
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1.635 Methotrexate (MTX) 
Methotrexate is often the first choice second-line drug. It acts relatively quicker than 
the other second-line drugs; being within several weeks after commencement of 
therapy. 
MTX decreases serum levels of IgM, IgG and IgA rheumatoid factor and 
mononuclear cells (Olsen et al., 1987; Olsen & Murray, 1989). It also reduces IL-1 
production from mononuclear cells (Thomas & Carroll, 1993), and suppresses clonal 
growth of T and B cells and proliferating fibroblasts (Nakajima et al., 1996). After 
rapid uptake by the cells, MTX is metabolized to a family of polyglutamated 
derivatives that persist intracellularly. The metabolites could enhance the release of 
adenosine (A!) that would inhibit neutrophil adhesion and down regulates the 
generation of free radicals of oxygen. The side effects associated with the use of 
methotrexate are summarized in Table 1.64. 
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Table 1.64 Side effects of methotrexate 
Systems affected Effects References 
Gastrointestinal Vomiting Griffith et al, 2000 
Dermal Granulomatous vasculitis Gxof^et al, 1983 
Hepatic Fibrosis, Phillips et al., 1992 
Malignant transformation 
Haematopoetic Leucopenia Weinblatt et al, 1992 





Respiratory Shortness of breath, Kremer et al., 1997 
Cough 
Reproductive Oligospermia, Sussman & Leonard, 1980 
Impotence, 
Gynaecomastia 
Skeletal Osteoporosis Friedlaender et al, 1984 
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1.64 New trends for treatment of arthritis 
None of the presently available anti-arthritic drugs can treat the course of the disease. 
Although second-line drugs showed better results, their actions are often associated 
with severe toxic effects. Therefore, the search for better anti-arthritic therapies 
continues. In the following, some of the new anti-arthritis strategies are reviewed. 
1.641 Anti-cvtokine therapy 
Cytokines are the main mediators of inflammatory processes. Therefore, the cytokine 
cascade system is a reasonable target for treatment of inflammatory joint diseases. 
Monoclonal anti-bodies against TNFa, IL-6 and IL-1 have been tested in clinics 
(Dinant & Dijkmans, 1999; Jorgensen et al., 1999). Both of them showed significant 
short-term beneficial effects. IL-1 monoclonal antibodies were shown to have 
efficacies even in the recovery of chondrocyte synthesis and suppressing cartilage 
destruction. However, therapies with anti-cyokine antibodies are associated with a 
high risk of serious infections. 
New trials now aim to combine the anti-cytokine therapy with second-line drugs 
(Forre et al, 2000). Other trials are based on increasing the anti-inflammatory 
cytokine levels. For example, gene therapy for delivering IL-13, which reduces the 
actions of macrophages, has been tested and shown to be effective in reducing the 
actions of some inflammatory mediators. However, the true anti-arthritic efficacy of 
this approach still requires further evaluation. 
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1.642 Anti-angiogenesis therapy 
The degree of vascularity in the affected joints of arthritis patients is higher than 
normal. Anti-angiogenesis therapy is thought to be a possible approach for slowing 
down all progression of arthritis disease. Some anti-rheumatoid drugs e.g. 
indomethacin, gold-salt and sulfasalazine have already been shown to reduce new 
blood vessel formation. Angiostatic steroids, e.g. 2-methoxyestradiol have been 
shown to suppress type-II collagen-induced arthritis in mice (Oliver et al., 1994). 
Minocycline and dexyspergualin are new angiogenesis-inhibitors. Monocycline has 
been shown to suppress both adjuvant- and collagen-induced arthritis in rats (Sewell 
et al., 1996), and deoxyspergualin abrogates type II collagen-induced arthritis in 
mice (Oikawa et al., 1992; Oikawa et al., 1991). The therapeutic efficacy of this 
approach remains to be elucidated. 
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1,7 Aims of the current study 
Arthritis is a global disease, affecting 1 % of the population worldwide and 0.35% of 
the population in Hong Kong. The aetiology of this disease is uncertain but it is 
manifested as a chronic polyarthritis with intermittent acute inflammatory episodes. 
There are many practical and ethical issues that limit laboratory investigations of the 
disease in human subjects. Hence, the first objective of this project is to establish an 
animal model of the disease that would allow investigations on the pathophysiology 
of the disease without the use of human subjects. Inbred stains of rats are usually 
employed for the development of arthritis models. In this project, both inbred and 
outbred stains of rats will be tested for their suitability as an arthritis model. 
There is much evidence supporting the involvement of the nervous system in 
determining the pattern and severity of arthritis. One of the likely neurogenic 
mediators is SP, which is a tachykinin contained in sensory fibres. Previous studies 
have shown that this tachykinin is important in the initiation and perpetuation of 
acute arthritis, but its contribution in the development of chronic arthritis is unknown. 
Hence, after establishing a model of chronic arthritis, the actions of SP on the 
development of the chronic arthritis model will be investigated. Moreover, selective 
tachykinin receptor antagonists will be used to elucidate the receptor types mediating 
the SP-induced responses. The selective tachykinin antagonists will also be examined 
for their efficacies in inhibiting the arthritis symptoms. 
Current anti-inflammatory therapies, mainly cyclo-oxygenase inhibitors, reduce 
acute inflammation with little, if any, overall effect on the course of the disease. Thus, 
the slow acting anti-rheumatoid drugs remain an essential part of the therapeutic 
armamentarium in arthritis. However, the least toxic of these agents are also the least 
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efficacious. Many rheumatologists favour the use of steroids as an alternative 
treatment for arthritis because their effects are prompt and dramatic. However, 
prolonged use of these drugs leads to serious disabling toxic effects. Moreover, 
steroids do not alter the course of the disease, and bone and cartilage destruction 
continues while inflammation is decreased. Thus, the therapy for this disease remains 
largely nonspecific and empiric. 
In view of the plethora of pathways and mediators that are involved in the 
pathogenesis of arthritis, it is unlikely that the use of any single agent could offer 
total relief of the disease symptoms. Of the current anti-arthritic agents, steroids 
possess the broadest spectrum of anti-inflammatory activities. Therefore, in spite of 
their shortfalls mentioned above, they are the most effective and preferred agent in 
treatments of the more severe forms of arthritis. As an attempt to improve the steroid 
therapy for arthritis, the final objective of this project is to investigate whether the 
anti-arthritic efficacies of steroids could be enhanced by co-administration with 
tachykinin receptor antagonists. 
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Chapter 2  
Material & drugs 
2.1 Materials and solutions 
Stock drug solutions were prepared as described below. Subsequent dilutions of all 
stock solutions for use in experiments were made in physiological saline (0.9% 
NaCl). 
Acid alcohol (1%) was prepared by slowly adding 1ml concentrated hydrochloric 
acid to 99ml 70% ethanoL 
Formalin buffer (10%) was prepared by dissolving 4g NaHiPC^HiO (BDI 
Laboratory Supplies) and 6.5g Na2HP04 (BDI Laboratory Supplies) in distilled water. 
Formaldehyde (100ml) was added and made up to 1000ml with distilled water, and 
stored at room temperature. 
Formic acid (10%) was prepared by slowing adding 100ml formic acid (Merck) to 
900 ml distilled water, and stored at room temperature. 
Acetone (Merck) was stored at room temperature. 
Dexamethasone 21-phosphage (Sigma) was dissolved in physiology saline at 
required concentration. 
Entellan (microscopy, Merck) was stored at room temperature. 
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Eosin Y yellowish solution was prepared with 1% Eosin yellowish (BDI Laboratory 
Supplies, England) and 0.05% CaCl! (BDI Laboratory Supplies) dissolved in 
distilled water, and stored at room temperature. 
Ethanol (Merck) was stored at room temperature. 
Evans blue (BDH Laboratory Supplies, England) was freshly prepared from 
physiology saline at 50mg/mL 
Freund's complete adjuvant (FCA) was purchased from Sigma and stored at 2 °C -
8 � C . 
Lillie-Mayer Haematoxylin was prepared by dissolving 50g NH4SO4 AI12H2O (BDI 
Laboratory Supplies) in 700ml boiling distilled water and then added heamatoxylin 
monohydrate (5g) (BHH Laboratory Supplies) and 0.3g Sodium iodate (Sigma). 
When cooled, 300ml glycerol (BDH Laboratory Supplies) and 20ml acetic acid 
(Merck) were added. After passing through filter paper, the solution was stored at 
room temperature. 
Paraffin Wax (Merck, histosec) was stored at room temperature and melt at 65°C 
when used. 
Phosphate buffer saline (PBS) was prepared with 2.6g Nal^POAHiO (BDI 
Laboratory Supplies), 11.5g Na2HP04 (BDI Laboratory Supplies) and 8.5g NaCl 
(Sigma) dissolved in 1000ml distilled water, and kept at room temperature. 
Scott's Tap Water consists of 2mg/ml potassium bicarbonate (BDI Laboratory 
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Supplies) and 20mg/ml magnesium sulphate (BDI Laboratory Supplies) dissolved in 
distilled water. 
Sodium sulphate (Sigma) was dissolved in distilled water and stored at room 
temperature. 
Substance P (Sigma) was dissolved in distilled water as lOmM stock solution and 
stored at -20°C. 
Thiopentone sodium (Abbott) was kept below 30°C and dissolved in physiology 
saline. 
Urethane (Ethyl carbanate, Sigma) was dissolved in physiology saline at 0.25g/mL 
Xylene (Merck) was stored at room temperature. 
2.2 Antagonist preparations 
CP99994，[(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] (kindly donated 
by Prof. Rudd. John, CUHK) was dissolved in physiology saline. 
RP67580, {(3aR,7aR)-7,7-diphenyl-2-[imino-2-(2methoxyphenyl)ethyl]perhydroiso 
indol-4-one} (generously provided by Rhone-Phulenc Rorer, France) was prepared as 
50mg/kg stock solution in absolute ethanol and stored at -20°C. 
SR140333, (S) 1 -{2-[3-(3,4-dichlorophenyl)-1 -(3-isopropoxyphenylacetyl)piperidin-
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3-yl] ethyl}-4-phenyl-1 -azoniabicyclo[2.2.2]octane chloride (generously supplied by 
Sanofi Recherche, France) was dissolved at concentration of 40mg/ml in DMSO and 
stored at -20 °C. Subsequent dilution was made in physiology saline. 
SR142801, (S)-(N)-( 1 -(3 -(1 -benzoyl-3 -(3,4-dichlorophenyl)piperidin-3 -yl)propyl)-4 
-phenylpiperidin-4-yl)-N-methyl acetamide (kindly supplied by Sanofi Recherche, 
France) was dissolved at concentration of 40mg/ml in DMSO and stored at -20 °C. 
Serial dilutions' to the required concentration with physiology saline. Subsequent 
dilution was made in physiology saline. 
SR48968, (S)-N-methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichloroph 
enyl) butyl) benzamide) (kindly supplied by Sanofi Recherche, France) was 
dissolved in absolute ethanol as lOmg/ml stock solution and stored at -20°C. 
Subsequent dilution was made in physiology saline. 
The chemical structures of these antagonists are shown in Figure 2.1 
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3.1 Animal use and anaesthetisia 
Animals used in this project were Lewis rats and Sprague-Dawley (SD) rats. Acute 
experiments were performed on 250-300g rats, whereas, chronic experiments were 
performed on 200g rats. The animals were bred and kept in the University 
Laboratory Animal Services Centre. Each cage was supplied with sufficient food and 
water. 
For the induction of arthritis, rats were anaesthetized with 40mg/kg sodium 
pentobarbitone injected intra-peritoneally. For acute experiments, such as 
measurement of Evans blue extravasation, knee joint blood flow, and histological 
studies, rats were anaesthetized with intraperitoneal injection of 2mg/kg urethane. 
Once anaesthetized, the animals were constantly kept under observation to ensure 
that breathing was slow and regular. Deep anaesthesia was indicated by the abolition 
of withdrawal reflex when the hindpaw of the rat was squeezed. 
3.2 Measurement of plasma protein extravasation 
The method of Evans blue extravasation was employed to determine the changes in 
vascular permeability. It relies on the fact that Evans blue dye has high binding 
affinity to plasma protein. Normally, the large plasma proteins and the bound Evans 
blue dye cannot pass through the endothelial gaps and they are therefore restricted in 
the vascular compartment. However, when the endothelial gaps are enlarged, the 
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plasma protein-Evans blue dye complex can escape to the intestitial tissues. Thus, 
measurement of the amount of Evans blue dye in the synovial capsule can provide an 
index of the relative vascular permeability. 
In the present study, 50 mg/kg of Evans blue dye was administrated via the jugular 
vein into the rats under anesthesia. After four hours, the anterior and posterior 
synovial capsules and fat pad were dissected out from each knee joints. The tissues 
obtained from each knee joint were small, thus, tissues from 4 knees were grouped to 
form one sample. The samples were then weighed, and the amount of Evans blue in 
the samples was estimated using a modified dye extraction technique (Harada et al., 
1971). This entailed cutting the capsules into smaller pieces and mixing them with 
acetone and 1% NaS04 in ratio of 7:3. The samples were shaked mildly and 
continuously for 24 hours in room temperature. Each preparation was then 
centrifuged for 10 minutes at 200rev/minute and 2 ml of the supernatant was 
separated for measurement of absorbance at 620mn using a Pharmacia Biotech 
spectrophotometer. The amount of dye extracted was calculated by comparing the 
absorbance of the fluid with that of a standard curve prepared with known 
concentrations of Evans blue solution. 
3.3 Measurement of knee joint sizes 
On the anaesthetized rat, the skin over the medial aspect of the knee joint was 
excised. Digital micrometer (Mitutoyo) was placed across the medial aspect of the 
knee joint holding the muscles on either side at appropriate strength. The reading on 
the micrometer was then noted. 
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3.4 Measurement of knee joint blood flow 
The method of laser Doppler imaging (LDI) described by Lam and Ferrell (1993) 
was used to measure the knee joint blood flow. Rats were anaesthetized as described 
above, and then the skin over the knee joint was removed to expose the antermedial 
aspect of the joint capsule. A laser Doppler perfusion imager (Moor Instrument Ltd., 
England) placed 60 cm above the joints, directs a helium-neon laser (630nm) to the 
tissue and scans the surface of the joint in a square pattern of 7.5X7.5cm in 
approximately 1 minute. This allowed simultaneous scanning of opposite knees of 
two separate rats placed in close proximity. At each measurement site, the beam 
penetrates the tissue to a depth of at least 250 lam. In the presence of red blood cells 
circulating in the capillaries, partially backscattered Doppler-broadened light is 
detected by a photodetector in the scanner head which converts the instantaneous 
light intensity into an electrical signal (in flux) that is proportional to tissue perfusion. 
A colour-coded perfusion image can subsequently be generated and displayed on the 
monitor. The actual perfusion (flux) values at each point in the image are stored on 
disc and can be utilized for calculation of the mean perfusion within a given area 
using a VIEW software (Moor Instrument Ltd., England). The area selected is based 
on the criterion that it should include most of the articular tissue with minimal 
inclusion of the relatively less well-perfused muscle around the joint. Each joint was 
scanned three times with 2 minutes intervals in between. Results were expressed as 
the mean flux values 士 s.e.mean of selected areas the LDI images. 
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3.5 Measurement of histological changes 
Rat knee joints were prepared for heamatoxylin and eosin (H&E) staining for 
assessment of histological changes by the following steps. 
Step I: Dissection and fixation of the knee joint 
Rats were deeply anesthestized with urethane, the skin covering the knee joints was 
excised. The knee joints were dissected from about 0.5 cm above and below the 
patella, and muscles of the dissected knees were removed as much as possible as they 
affect processing time. The dissected knees were rinsed with 0.9% saline to wash off 
the blood. They were placed in 10% formalin with mild agitation for fixation for 7 
days. The fixative was replaced with a fresh solution after four days. 
3.52 Step II: Decalcification 
In order to ease the sectioning of the joints, it is necessary to remove the minerals in 
the bone and thus soften the tissue. This was carried out by treatment with reagents 
that can react with calcium in the cartilage and bone such as acids that can form 
calcium salts or a chelating agent that can take up calcium ions. In this project, two 
decalcifiers had been tested: 10% formic acid and a commercially available 
decalcifying agent. The latter required shorter decalcification time, but was 
unsatisfactory for staining, and hence, 10% formic acid was chosen as the decalcifier 
in this project. 
The knee joint was immersed in 10ml of the 10% formic acid solution for 8 days. 
The solution of formic acid was changed after four days. 
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After decalcification, the sample was rinsed with running water for 6 hours to wash 
off the acid as it would affect the staining of the samples. It was then stored in 
phosphate buffer saline (PBS) until further processing. 
Step 3: Processing 
A processing machine (Shandon, Duplex Processor) was used for dehydration, 
clearing and wax infiltration of the joint. Serial increasing concentrations of alcohol 
were employed in the dehydration steps and then xylene was used for removing of 
the alcohol and clearing of the joints. Full xylene penetration was crucial for success 
of the subsequent steps of wax infiltration in molten paraffin wax. Each of the 
processing steps required to be performed under agitation of the solutions. 
Dehydration was performed by 3 hours serial incubation in 70%, 80% and 95% 
ethanol, followed by 6 hours incubation in 100% ethanol with replacement of fresh 
absolute ethanol every 2 hours. Clearing was performed by incubation in xylene for 
2.5 hours with replacement of fresh xylene after 1 hour. The timing of this clearing 
step is critical, as the tissue would be two stiff if incubated in xylene for too long, 
and wax infiltration is not possible if incubated for too short. Wax infiltration was 
achieved by immersion of the samples three times in molten wax, each time for 2 
hours. 
3.54 Step 4: Embedding 
An embedding machine (Histocenter 2，Tissue Embedding Centre) was used. The 
knee joint sample was kept in heated wax to avoid air exposure. It was then 
embedded with wax in an embedding mould and embedding ring, with the patella 
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orientated towards the posterior side of the embedding mould. The sample was 
quickly placed onto a cold plate for 5 minutes to fix the position, and then kept at 
4°C for 3 hours. The embedded sample was then stored in room temperature. 
3.55 Step 5: Sectioning 
The embedded sample was serially sectioned to 5 |im thick slices with a microtome 
(model no:RM2125RT, Leica). One in every 20 sectioned slices was selected and 
floated on 3 7 � C water bath (Leica) for 1 minute and then mounted on glass slides. 
To dry and fix the sections, the glass slides were kept at 37 °C for 12 hours. 
3.56 Staining 
Staining of the knee joint sections involved dewaxing, dying, and dehydrating of the 
tissue. Dewaxing was achieved by baking the slides in an oven for 10 minutes at 
65°C. They were then placed in xylene for 10 minutes incubation. Hydration was 
accomplished by placing the slides in 100 % ethanol for 5 minutes, followed by 3 
minutes serial incubation in 95%, 85%, 70% and 50% alcohol. The samples were 
then rinsed under running water for 2 minutes. 
The sections were first dyed with haematoxylin for 10 minutes, and then washed 
under running water for 2 minutes. Non-specific staining was removed by three dips 
in 1% acid alcohol. Then, the colour of heamatoxylin remained was enhanced by 
incubation in ‘Scott, tap water for 1 minute and then running water for 2 minutes. 
The slides were then immersed in eosin for 8 minutes, and then dehydrated by serial 
incubation with 70%, 85%, 95%, and 100% (thrice) alcohol for 1, 2, 3，and 5 minutes 
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respectively. Eosin is highly soluble in water, and thus extra care was taken to ensure 
that the specified incubation time was adhered to. After dehydration, the slides were 
incubated in xylene for 20 minutes to remove the alcohol. Small amount of enterlin 
(Merck) was used to allow mounting of the coverslips onto the slides and to achieve 
a refractive index near to that of glass. 
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3.6 Data analysis 
Results obtained from Evans blue extravasation, joint size and basal blood flow were 
expressed as means土s.e.mean, in unit of |ag/g tissue of Evans blue extravasated, mm 
and flux, respectively. Differences between curves were analyzed by two factor 
analysis of variance (ANOVA), followed where appropriate by comparisons of 
means by Planned Contrasts (Super ANOVA, Abacus Concept, USA). The latter 
procedure is very efficient for comparing a limited subset of possible contrasts. This 
is useful for testing hypotheses about data that are more specific than the hypothesis 
automatically tested for each term in the ANOVA model (Gagnon et al” 1989). 
Differences between means on a dose-response curve were analyzed by one factor 
ANOVA followed by Planned Contrasts. Results on single dose treatments were 
analyzed by paired or unpaired Student's Mest as appropriate. P values <0.05 were 
considered statistically significant. 
Histological evaluation was performed by an independent observer using a visual 
scoring scale from 1 to 5 based on criteria outlined in Table 3.1. Each of the 
parameters was evaluated twice and performed on different days. 
3.61 Scoring systems 
Sections of the middle part of the joint were selected, so that two full menisci can be 
observed in the same slide. Immune cell infiltration, synovial tissue proliferation, 
growth of collagen web in the fat pad, cartilage degradation and bone erosion were 
graded according to the criteria summarized in Table 3.1. 
For immune cell infiltration, the criteria to be considered are the cell density and the 
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spread of the immune cells in the synovial tissues. Sections of the middle part of 
the joint (A) were used for assessment of the density of immune cell accumulation 
and sections of the superficial layer of the synovial capsule (B) were used for the 
assessment of spread of the infiltrated immune cells. 
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Table 3.1 Scoring criteria for histological changes 
Scores 1 2 3 4 5 
Changes\^ 
^ *(A) <20% (A) 20-50% (A) 50-70% (A) > 70% (A) >70% 
infiltration #(B)None (B) None (B) <20% (B) 20-50% (B) >50% 
Synovial Mild Severe One of the Any two of All of the 
tissue thickening of thickening of following the observations 













Growth of <20% 20-40% 40-60% 60-80% 80-100% 
collagen web 
in the fat 
pad  
Cart i lageSynov ia l Synovial Cartilage Loss of No defined 
degradation tissue began tissue shape became cartilage cartilage 
to appear on invades the irregular thickness structure 
cartilage cartilage  
Bone erosion No defined Slight bone Mild bone Severe bone Severe bone 
cartilage erosion trabecular trabecular trabecular 
structure occurred erosion erosion erosion and 
new bone 
formation 
* (A) Density of immune cell accumulation 
# (B) Degree of spreading of infiltrated immune cells 
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Chapter 4 
A model of monoarthritis in rats 
4.1 Introduction 
At present, experimental animal models provide the only means of investigating 
conditions that resemble human diseases without the use of human subjects. For the 
study of human joint diseases, many animal models of arthritis have been developed 
and these have been discussed in the previous chapter. The classical one is adjuvant-
induced arthritis in the rat, which involved injection of heat killed tuberculosis 
bacteria at the base of the tail to cause the development of a highly erosive 
polyarthritis. The condition is accompanied with severe and extensive disease, 
systemic illness and profound weight lost of the animal. 
The widespread systemic effect in the above adjuvant-arthritis model could 
complicate investigations on the joint disease. Donaldson et al. (1993) first attempted 
to limit the systemic effects of animal arthritis models by testing the injections of 
varying dosages of adjuvant in the rat. By this approach, they have limited the 
widespread systemic complications to the first 30 days, and produced a more discrete 
arthritis as a result. Recently, Dowed and colleagues (1998) have described a method 
of producing a monoarthritis model that is devoid of systemic complications. It 
simply involved unilateral injection of a small dose of adjuvant into synovial cavities 
of the rat knee j oint. 
Traditionally, inbred animals were more favourable than outbred animals for use in 
the development of animal arthritis model because the former was thought to give 
more consistent arthritis symptoms (Nordquist et al., 2000). This assumption was 
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tested in the present study by comparing the use of inbred Lewis rats and outbred 
Sprague-Dawley (SD) rats for the monoarthritis model described by Dowed and co-
workers (1998). 
4.2 Method 
Inbred Lewis rats or outbred SD rats weighing 250 to 300g were anesthetized with 
40mg/kg thiopentone. One of the rat knee joints on each animal was injected with 0.1 
ml of Freunds, complete adjuvant (FCA) containing O.lmg Mycobacterium 
tuberculosis; the contralateral knees were injected with 0.1ml physiological saline as 
control. After 1, 3, 7，14 or 28 days, vascular permeability, joint size and blood flow 
were measured by Evans blue extravasation, a digital micrometer, and a laser 
Doppler perfusion imager, respectively. Histological changes that include immune 
cell accumulation, synovial tissue proliferation, cartilage degradation, and bone 
erosion were assessed after the joints had been processed and stained with 
haematoxylin and eosin. 
4.3 Results 
4.31 Lewis rats 
Injection of FCA in the knee joints of Lewis rats produced significantly greater 
amount of Evans blue extravasation compared with their contralateral saline-injected 
knees (n=5-6; P<0.001; two factor ANOVA; Figure 4.1) which were most obvious 
from day 1 to day 7 (n=5-6;尸<0.001 for both; Planned Contrasts). Joint swelling was 
also significantly greater in the FCA-injected knees than those of contralateral knees 
(n=ll-32;户<0.001; two factor ANOVA; Figure 4.2) throughout the 28 days assessed 
(n=ll-32;尸<0.001 for both; Planned Contrasts). The basal blood flow of FCA-
injected knees and the contralateral saline-injected were not significantly different 
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(n=12-28; P>0.05; two factor ANOVA; Figure 4.3), except on day 3 and day 14 
(P<0.05 for both; Planned Contrasts). 
4.32 SD rats 
The effects of unilateral intra-articular injection of FCA on SD rats were much the 
same as those observed on Lewis rats. Thus, the FCA-injected knees of SD rats 
produced significantly greater Evans blue extravasation compared with their 
contralateral saline-injected knees (n=5-8; P<0.001; two factor ANOVA; Figure 4.4). 
Again, the differences were most obvious during the first week (n=4-6; P<0.001 for 
both; Planned Contrasts). Joint swelling was also more significant in the FCA-
injected knees throughout the 28 days (n二 18-27;尸<0.001 for both; two factor 
ANOVA; Figure 4.5). Basal blood flow was not significantly different between FCA-
injected knees and contralateral saline-injected knees (n= 12-28; P>0.05; two factor 
ANOVA; Figure 4.6) except on day 7 (P<0.05; Planned Contrasts). 
4.33 Comparison of FCA-induced changes in Lewis and SD rats 
Although unilateral intra-articular injections of FCA produced essentially the same 
changes on the Lewis and SD rats, there were some minor differences: SD rats had 
greater Evans blue extravasation and more obvious on day 3 (n二5-7;尸<0.05; two 
factor ANOVA and P<0.001; Planned Contrast; Figures 4.7A). In addition, joint 
swelling was less pronounced in Lewis rats compared with SD rats throughout 28 
days, except at day 3 (n二 12-32;尸<0.05; two factor ANOVA and P<0.001 for day 1 
and day 3; P<0.01 for day 14 and P<0.05 for day 28; Planned Contrasts; Figure 
4.7B). However, Lewis rats showed greater changes of basal blood flow than those of 
SD rats, especially at day 3 and day 14 (P<0.001; two factor ANOVA and 尸<0.01-
0.001; Planned Contrasts; Figure 4.7C). 
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4.34 Histological studies on arthritic SD rats 
As shown in Figures 4.8 and 4.9, accumulation of immune cells occurred 
progressively and bilaterally in the infra-patella fat pads of the arthritic SD rats, and 
the level of immune cell accumulation in the FCA-injected knees was significantly 
higher than that in the contralateral saline-injected knees, the differences was more 
obvious from day 3 onwards (n二3; P<0.001; two factor ANOVA and P<0.001; 
Planned Contrasts). Similarly, growth of collagen web occurred progressively from 
day 3 onwards and bilaterally in the infra-patella fat pads of these animals (n=3; 
尸<0.001; Planned Contrasts; Figures 4.8 and 4.10), and growth was more prominent 
in the FCA-injected knees compared with the contralateral saline-injected knees 
(n=3;户<0.001; two factor ANOVA). 
Again, Synovial tissue proliferation was more prominent from day 3 onwards and in 
the FCA-injected knees compared with the contralateral saline-injected knees (n=3; 
P<0.001 for both; Planned Contrasts and two factor ANOVA). Growth of synovial 
tissues on the menisci appeared from day 3 onwards in the FCA-injected knees, but 
small traces of tissue only began to appear on day 14 in their contralateral knees 
(Figure 4.11). In addition, the proliferating capsules began to attach onto the bones on 
day 14 in the FCA-injected knees (Figure 4.14). The effects on synovial proliferation 
are summarized in Figure 4.13. 
FCA-injected knees showed progressive cartilage degradation from day 7 onwards, 
but their contralateral saline-injected knees were not affected (n=3;尸<0.001; Planned 
Contrasts and two factor ANOVA; Figures 4.14 and 4.15). The effect of FCA 
injection on bone degradation was similar to that on cartilage degradation, but the 
onset day is from day 14 onwards and the contralateral knees were again unaffected 
(n=3; P<0.001; Planned Contrasts and two factor ANOVA; Figure 4.14 and 4.16). 
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Figure 4.1 
Effects of intra-articular injection of FCA on Evans blue extravasation in knee joints 
of Lewis rats. FCA-injected knees produced significantly greater amount of Evans 
blue extravasation compared with their contralateral saline-injected knees (n=5-8; 
***尸<0.001; two factor ANOVA). Subsequent analysis by Planned Contrasts showed 
that the FCA-injected knees had higher Evans blue extravasation than their 
contralateral saline-injected knees from day 1 to day 7 (###尸<0.001). Data are shown 
as means 士s.e.mean (shown by vertical lines) of the amount of Evans blue 
extravasated in |ag/g tissue. 
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Figure 4.2 
Effects ofintra-articular injection of FCA on knee joint sizes of Lewis rats. The sizes 
of FCA-injected knees were significantly larger than those of their contralateral 
saline-injected knees from day 1 to day 28 (n=ll-32; ***尸<0.001; two factor 
ANOVA; ###P<0.001; Planned Contrasts). Data are shown as means 土s.e.mean 
(shown by vertical lines) of the joint size in mm. 
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Figure 4.3 
Effects of intra-articular injection of FCA on knee joint blood flow of Lewis rats. 
There was no significant difference in blood flow between the FCA-injected and the 
contralateral saline-injected knees (n=ll-32;尸>0.05; two factor ANOVA). 
Subsequent analysis by Planned Contrasts showed that the FCA-injected knees had 
significantly higher blood flow than their contralateral saline-injected knees on day 3 
and day 14 (n=19-24; #P<0.05). Data are shown as means 士s.e.mean (shown by 
vertical lines) of the joint perfusion expressed in flux. 
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Figure 4.4 
Effects of intra-articular injection of FCA on Evans blue extravasation in knee joints 
of Sprague-Dawley (SD) rats. FCA-injected knees produced significantly greater 
amount of Evans blue extravasation compared with their contralateral saline-injected 
knees (n=5-8; ***P<0.001; two factor ANOVA), the effect was more obvious at day 
1, 3 and 7 (冊#P<Q.001; Planned Contrasts). Data are shown as means 土 s.e.mean 
(shown by vertical lines) of the amount of Evans blue extravasation in |Lig/g tissue. 
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Figure 4.5 
Effects of intra-articular injection of FCA on knee joint size of SD rats. The sizes of 
FCA-injected knees were significantly larger than those of their contralateral saline-
injected knees for all days (n=18-27; ***P<0.001; two factor ANOVA; #獄<0.001; 
Planned Contrasts). Data are shown as means 土 s.e.mean (shown by vertical lines) of 
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Figure 4.6 
Effects of intra-articular injection of FCA on knee joint blood flow of SD rats. There 
was no significant difference in blood flow between the FCA-injected and the 
contralateral saline-injected knees (n= 12-28;户>0.05, two factor ANOVA). However, 
subsequent analysis by Planned Contrasts showed that the FCA-injected knees had 
significantly higher blood flow compared with their contralateral saline-injected 
knees on day 7 (n= 12-28; #P<0.05). Data are shown as means 土s.e.mean (shown by 
vertical lines) of the perfusion expressed as flux. 
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Figure 4.7 
Comparisons of FCA-induced (A) Evans blue extravasation, (B) joint size & (C) 
basal blood flow in Lewis rats and SD rats. The increases in (A) Evans blue 
extravasation (n=5-7; *P<0.05; two factor ANOVA) and (B) joint sizes (n= 12-28; 
***P<0.001; two factor ANOVA) in SD rats were greater than those of Lewis rats, 
and were most obvious on day 3 for Evans blue extravasation (##P<0.01; Planned 
Contrasts) and day 1 to day 28, except on day 3 for joint size (n=5-32;冊P<Q.O\; 
###P<0.001; Planned Contrasts). However, Lewis rats had greater increase in basal 
blood flow than those of SD rats (n=12-28; ***P<0.001; two factor ANOVA), and the 
difference was more obvious on day 3 and day 14 (##P<0.01; ###尸<0.001, 
respectively; Planned Contrasts). Data are shown as means 土s.e.mean (shown by 
vertical lines) of the means difference between the test FCA-injected and the 
contralateral saline-injected knees. 
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Figure 4.8 
Micrographs illustrating effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on immune cell infiltration and g owth of collagen webin rat knee joint. Accumulation of immune cel s (I) and invasion by col agen (C) inthe infrap tella fa pads of he FCA-injec d knees a d ont ala ral saline-i jectedknees w re bserved from day 1 and day 3 onwards. 
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Figure 4.9 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
immune cell infiltration in rat knee joints. FCA-injected knees produced significantly 
more immune cell accumulation compared with their contralateral saline-injected 
knees (n=3; <0.001; two factor ANOVA). The differences were more obvious 
from day 3 onwards (#P<0.05; ##尸<0.01; ###P<0.001; Planned Contrasts). Data are 
shown as means士s.e.mean (shown by the vertical bars) of the level of immune cell 
infiltration graded by the criteria described in “ Methodology" in chapter 3. 
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Figure 4.10 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
growth of collagen web in the infra-patella fat pads of rat knee joints. FCA-injected 
knees had significantly more collagen web growth compared with their contralateral 
saline-injected knees (n二3;嫩P <0.001; two factor ANOVA). The differences were 
more obvious from day 3 onwards (#P<0.05;鼎肝<0.001; Planned Contrasts). Data 
are sho種 as means士s.e.mean (shown by the vertical bars) of the level of collagen 
web growth graded by the criteria described in “ Methodology" in chapter 3. 
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Figure 4.11 
Micrographs illustrating effects of unilateral intra-articular injection of Freund's 
complete adjuvant (FCA) on synovial tissue proliferation at the tips of menisci in 
rat knee joints. In the FCA-injected knees, synovial tissues proliferation on the 
menisci occurred on day 3, whereas, in the contralateral saline-injected knees, they 
appeared on day 14. 
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Figure 4.12 
Micrographs illustrating effects of intra-articular injection of Freund's complete 
adjuvant (FCA) on synovial capsule thickness in rat knee joints. In the 
FCA-injected knee, capsule thickening from day 1 onwards and contacted the bone 
at day 14 (A), whereas, in the contralateral saline-injected knees, the capsule 
thickening was not so prominent throughout the 28 days. 
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Figure 4.13 
Effects of unilateral-intraarticular injection of Freund's complete adjuvant (FCA) on 
synovial tissue proliferation in rat knee joints. FCA-injected knees produced 
significantly greater synovial tissue proliferation compared with their contralateral 
saline-injected knees (n=3; ***尸<0.001; two factor ANOVA). The differences were 
more obvious from day 3 onwards (##P<0.01; ; Planned Contrasts). Data 
are shown as means土s.e.mean (shown by the vertical bars) of the level of synovial 
tissue proliferation graded by the criteria described in “ Methodology" in chapter 3. 
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Figure 4.14 
Micrographs illustrating effects of intra-articular injection of Freund's complete 
adjuvant (FCA) on cartilage and bone degradation in rat knee joints. In 
FCA-injected knees, the cartilage surfaces were intact on the first 3 days, but, they 
became irregular (C) on day 7. New bone formation (B) appeared on day 14. 
Cartilage plate was lost and the bone was eroded at day 28. In contralateral knees, 
cartilage and bone were intact throughout the 28 days. 
89 
• Saline-injected"! *** 
• FCA-injected」 
5 
c . 騰 i 
iS A 騰 
T5 ^ T  
L   
I ^ 
节3 z 
o ### / 
Ui T / ^ 2 / OJ • O / 
/ 
/ 
/ 1 / / 
/ 
_ X _ _ 
1 3 7 14 28 
Days post injection of FCA 
Figure 4.15 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
cartilage degradation in rat knee joints. Only the FCA-injected knees produced 
significant cartilage degradation (n=3; ***P <0.001; two factor ANOVA). The 
cartilage degradation was more obvious from day 7 onwards (###P<0.001; Planned 
Contrasts). Data are shown as means土s.e.mean (shown by the vertical bars) of the 
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Figure 4.16 
Effects of unilateral intra-articular injections of Freund's complete adjuvant (FCA) 
on bone erosion in rat knee joints. Only the FCA-injected knees produced significant 
bone erosion (n=3;嫩户<0.001; two factor ANOVA). The bone erosion was more 
obvious from day 14 onwards (###P<0.001; Planned Contrasts). Data are shown as 
meansis.e.mean (shown by the vertical bars) of the level of bone erosion graded by 
the criteria described in “ Methodology" in chapter 3. 
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Figure 4.17 
Summary on the structural changes of the FCA-induced monoarthritis model in the 
rat knee joint. From day 1 onwards, immune cells accumulated in the synovial tissue 
and synovial capsules were began to thicken reaching maximum thickness on day 14. 
Cartilage and bone damage occurred from day 7 and day 14 onwards, respectively. 
Beyond day 14, the orientation of the femur and the tibia was affected, resulting in 
deformation of the joint. 
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4.4 Discussion 
This study demonstrated that a single intra-articular injection of FCA could produce 
monoarthritis in both inbred Lewis rats and outbred SD rats. Changes in basal blood 
flow are not good indicators of arthritis because significant vasodilatation occurred 
only in some days in both species. In Lewis rats, the changes in joint size and on 
vascular permeability were of smaller magnitude and less consistent compared with 
those observed in SD rats. Therefore, the use of inbred Lewis rats does not offer any 
advantage over the use of outbred SD rats for this monoarthritis model. 
Characteristically, an arthritic human joint exhibits exudation of leucocytes in the 
synovial spaces and accumulation of these cells in the affected synovial tissues. 
Hyperplasia of synovial lining cells and proliferation of granulation tissue are also 
prominent. Destruction of subchondral bone and cartilage, with rapid production of 
new bone in the adjacent periosteum could also be present during the later course of 
the disease. All these morphological changes were observable in the present animal 
model of arthritis. Immune cell infiltration, development of collagen web in the 
intrapatella fat pads and synovial tissue proliferation were detected on day 3, and 
there was cartilage degradation beginning on day 7 (usually two years in human). 
Much of the arthritis symptoms appeared to be most severe on day 14 and there was a 
trend of gradual decrease in these symptoms towards day 28. 
The present study showed that immune cell accumulation and Evans blue 
extravasation do not occur in parallel. Thus, immune cell accumulation was 
observable throughout the 28 days but Evans blue extravasation was not present after 
the first two weeks. The reason may be that once immune cells are recruited by the 
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increased in vascular leakage at the early stage of the disease, they would interact 
with synovial tissues to release proinflammatory mediators such as the chemokines 
that would attract migration of immune cells (Buckley et al., 2000; Jarvis et al, 
1997). Hence, although there was no observable change in the endothelial gaps as 
indicated by the absence or low level of Evans blue extravasation at the later stages 
of the disease, immune cells could still be attracted and accumulate in the synovial 
tissues. 
Proliferation of fibroblasts would generate large amounts of adhesion molecules such 
as intergrin and vascular cell adhesion molecule (VCAM) that promote immune cell 
accumulation. The attracted immune cell would in turn activate the synoviocytes to 
proliferate. The proliferating fibroblasts would attach to the cartilage surface (Kraan 
et al., 2001; Morales-Ducret et al., 1992; Rinaldi et al., 1997; van Dinther-Janssen et 
al., 1994) and produce degradation enzymes e.g. collagenase (Moore et al., 2000) 
that mediate the progressive destruction of cartilage and bone. Thus, all the 
symptoms indicated in the present model are in mutual interaction with each other. 
Human arthritis often shows bilateral symmetry. The present study showed that in the 
contralateral saline-injected knees of the adjuvant-treated rats, there were small 
degrees of immune cell infiltration, synovial tissue thickening and collagen web 
development on day 3, 14 and 7 respectively. These findings indicate that signs of 
arthritis are beginning to develop in the contralateral knees of these animals. 




An animal model of monoarthritis induced by single intra-articular injection of FCA 
on outbred SD rats has been successfully established. This animal model showed 
many characteristics resembling those of the human disease such as increase in 
vascular permeability, joint swelling, accumulation of immune cells, synovial 
hyperplasia, cartilage degradation and bone erosion. The arthritis developed is 
relatively localized in one joint, and unlike conventional polyarthritis models, there is 
no systemic complication in the animal. Therefore, the present animal arthritis model 
represents a good alternative for the study of chronic arthritis in human. 
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Chapter 5 
The effects of Substance P on adiuvant-induced arthritis 
5.1 Introduction 
Substance P (SP) is a member of the tachykinin family consisting of a group of 
structurally related peptides including neurokinin A and neurokinin B. The 
tachykinins are known to produce biological responses via interactions with three 
major receptor types: the tachykinin NKi, NKi and NK3 receptors. SP displays the 
highest affinity for NKi receptor, but it can also act on other receptor types (Burcher 
et al, 1991; Mussap et al, 1993). 
Peripheral branches of sensory nerves are known to have dual "sensory-efferent" 
function such that activation of these neurones will increase afferent nerve discharge 
centrally as well as causing release of neuropeptides locally (Maggi et al., 1989). 
One of the neuropeptides contained in sensory neurones is SP (Gronblad et al., 1988; 
Konttinen et al., 1990; Walsh et al., 1992), and this acts as a neurotransmitter for 
nociceptive pathways when it is released at central sites (Hutchins et al., 2000; 
Kusaba et al., 2000). On the other hand, SP has been shown to be very widespread in 
the periphery (Quartara & Maggi, 1998), and it is transported to the peripheral 
sensory neurones at four times amount that it is transported centrally (Keen et al., 
1982). These findings indicate that it may have more important role(s) in the 
periphery, one of which is to mediate neurogenic inflammation. This is a condition 
first depicted by antidromic stimulation of nociceptive neurones leading to 
vasodilatation and increased vascular permeability in the area innervated by the 
stimulated nerve (Jancso et al., 1967; Lembeck & Holzer, 1979). 
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SP is implicated as a mediator of neurogenic inflammation because it has been 
shown that electrical stimulation of nerves supplying the cat knee joint can evoke the 
release of this peptide from articular nerve fibres (Yaksh, 1988) and produce plasma 
extravasation into the synovial cavity (Ferrell & Riissdl, 1986). This neurogenically 
induced plasma extravasation can be abolished by prior intra-articular administration 
of a SP antagonist (Ferrell & Russell, 1986). In addition, it has been shown that 
exogenously administered SP in rat knee joints causes dilation of the joint blood 
vessels (Lam & Ferrell, 1993a; Lam & Ferrell, 1993b) and increases their 
permeability (Scott et al., 1991). The latter response has been associated with the 
release of mediators from mast cells (Lam & Ferrell, 1990). SP has been shown in 
joints to exert other proinflammatory actions such as secretion of PGE2 and 
collagenase from synoviocytes (Halliday et al., 1993), secretion of IL-1-like activity 
from macrophages (Kimball & Fisher, 1988), and it may contribute to activation of 
the immune system (Singh, 1995). 
Nerve fibres containing SP are also present in the bone and synovial membrane of 
human j oints (Hukkanen et al, 1992) and the level of SP increased in synovial fluids 
of patients suffering from inflammatory j oint diseases (Menkes et al., 1993). 
The accumulated evidence suggests that SP is responsible for the neurogenic 
contribution to arthritis. In this part of the study, the effect of SP on the development 
of adjuvant-induced arthritis was investigated. 
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5.2 Method 
A rat model of monoarthritis described in the previous chapter was adopted for the 
present study. Sprague-Dawley rats weighing 250-3OOg were anaesthetised with 
sodium pentobarbitone (40 mg/kg). One of their knees were injected with 0.1ml 
Freimd's complete adjuvant (FCA); the contralateral knees were injected with 0.1ml 
physiological saline. Another group of rats, serving as controls, received injections of 
0.1ml saline in one knee; the other knee was left untreated. Arthritis symptoms in the 
knee joints were assessed after 1, 3, 7, 14, or 28 days. These include vascular 
permeability, joint size and blood flow changes, measured by Evans blue 
extravasation, a digital micrometer and a laser Doppler perfusion imager, 
respectively. Histological changes that include immune cell accumulation, synovial 
tissue proliferation, cartilage degradation, and bone erosion were also assessed after 
the joints have been processed and stained with haematoxylin and eosin. 
In another group of rats that had received FCA injections, additional injections of 
0.1ml (Inmol) SP were given in the same knees 4 hours prior to assessment of the 
arthritis symptoms; the contralateral knees were again injected with 0.1ml saline. 
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5.3 Results 
5.31 Evans blue extravasation 
As shown in Figure 5.1 A, unilateral intra-articular injections of FCA produced 
significant Evans blue extravasation compared with their contralateral saline-injected 
knees (n=5-8; P<0.001; two factor ANOVA) and this effect was more obvious from 
day 1 to day 7 (PO.OOl; Planned Contrasts). The contralateral Evans blue 
extravasation was lower than the saline-injected knees of control animals (n=5-6; 
_P<0.05; two factor ANOVA) and the effect was most obvious on day 3 (P<0.05; 
Planned Contrasts). 
Rat knee joints that had been injected with FCA plus SP showed significantly greater 
Evans blue extravasation compared with their contralateral saline-injected knees 
during the first week (n=5-6;尸<0.001; two factor ANOVA; P<0.001; Planned 
Contrasts; Figure 5.IB). The former rat knees also had higher Evans blue 
extravasation than the knee joints that had been injected with FCA alone from day 1 
to day 14 (n=5-8;尸<0.001; two factor ANOVA;尸<0.01-0.001; Planned Contrasts; 
Figure 5.1C). Significant contralateral Evans blue extravasation was also observed in 
the contralateral knees of FCA plus SP-treated rats compared with the saline-injected 
knees of control animals and the contralateral knees of the FCA-treated group (n=5-6; 
尸<0.001 for both; two factor ANOVA; Figures 5.IB & 5.ID). The former effect was 
sustained during the first two weeks (P<0.05-0.001; Planned Contrasts) while the 
latter effect lasted for 28 days (P<0.01-0.001; Planned Contrasts). 
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5.32 Joint size 
Injections of FCA produced significant swelling of the rat knee joint throughout the 
28 days compared with their contralateral saline-injected knees (n=18-27; i^O.OOl; 
two factor ANOVA; P<0.001; Planned Contrasts; Figure 5.2A). Joint sizes of the 
latter group were significantly larger than those of the saline-injected knees of 
control animals from day 7 onwards (n=20-28;尸<0.001; two factor ANOVA; 
尸<0.01-0.001; Planned Contrasts; Figure 5.2A). Joint sizes of the rat knees injected 
with FCA plus SP were also larger than those of their contralateral saline-injected 
knees throughout the 28 days (n=17-22; P<0.001; two factor ANOVA; P<0.001; 
Planned Contrasts; Figure 5.2B). The joint sizes of FCA-treated knees were the same 
with or without SP injection (n二 18-28; P=0.0804; two factor ANOVA; Figure 5.2C), 
except on day 7; FCA plus SP-treated knees had larger joint sizes than those received 
FCA treatment alone (n二 18-25;尸<0.001; Planned Contrasts; Figure 5.2C). Knee 
joint sizes of control animals that had received saline injection were smaller than 
those of the contralateral knees of FCA plus SP-treated animals (n=17-28; P<0.05 
two factor ANOVA; Figure 5.2A). This difference was more obvious on 14 (P<0.05; 
Planned Contrasts). The contralateral knees of FCA plus SP-treated group had 
smaller joint size than that of contralateral knees of FCA-treated group (P<0.001; 
two factor ANOVA) and this effect was more obvious on day 7 and day 28 (P<0.001 
for both; Planned Contrasts). 
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^ K n e �b l o o d flow 
AS shown in Figure 5.3A, blood flow of FCA-injected knees and its contralateral 
saline-ir^ected knees were the same (n=12-2S; P>0.05; two factor ANOVA), except 
on day 7; FCA-injected knees had higher blood flow than contralateral knees (n二22; 
P<0 05 Planned Contrasts). The saline-injected control knees had lower blood flow 
than saline-injected contralateral lo^ees and FCA-injected knees (P<0.05 for both; 
two factor ANOVA; Figure 5.3A). The fonner was more obvious on day 28 (iM).05; 
Planned Contrasts) and the latter was more obvious on days 3, 7 and 28 (尸<0.05; 
Planned Contrasts). 
Rat knees that had received unilateral injections of FCA plus SP had higher blood 
flow than their contralateral saline-injected knees and this effect was more obvious 
on day 1 and day 14 (n二 13-20; P<0.001; two factor ANOVA;尸<0.05; Planned 
Contrasts; Figure 5.3B). When compared with saline-injected knees of the control 
group and contralateral knees of FCA-treated group, the contralateral knees of FCA 
plus SP treated animals had higher blood flow throughout the 28 days (n二 13-20; 
P<0.001 for both; two factor ANOVA; P<0.05-0.001; Planned Contrasts; Figures 
5 3B and 5.3D). Blood flow of rat knees that had been injected with FCA plus SP 
was also significantly higher than those injected with FCA alone throughout the 28 
_ except day 7 ( n :蘭；P < 0 . 0 0 1 ; two factor ANOVA; ？顺糊！； Planned 
Contrasts; Figure 5.3C). 
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f>.34 Histology results 
I n f i l t r a t i o n o f i m m u n e cells in synovial tissue 
As shown in the micrographs of Figure 5.4 and in Figure 5.6A，unilateral 
intra-articular injections of FCA produced accumulation of immune cells in the 
infrapetalla fat pads from day 1 onwards; the highest density of immune cells were 
found on days 14. To a smaller extend, accumulation of immune cells also occurred 
in their contralateral saline-injected joints (Figures 5.5 and 5.6A). 
Similarly, unilateral injections of FCA plus SP produced accumulation of immune 
cells bilaterally. The extent of immune cell accumulation was similar in the FCA 
plus SP-injected knees and the FCA-injected knees (n二3; P>0.05; two factor 
ANOVA; Figures 5.4 and 5.6C). However, the contralateral knees of the FCA plus 
SP-treated group had higher density of immune cells. This was more obviously on 
day 1 compared with the contralateral knees of the FCA-treated group (n=3; P<0.05; 
two factor ANOVA; P<0.05; Planned Contrasts), as shown in Figures 5.5 and 5.6D. 
^ Synovial tissue proliferation 
Unilateral intra-articular injections of FCA promoted the growth of synovial tissues. 
In FCA-treated knees, the thickness of the capsule increased from day 3 onwards, 
and made contact to the bones on day 14; their contralateral knees were not affected 
(Figures 5.7 and 5.8). Growth of synovial tissues on the menisci appeared from day 3 
onwards in the FCA-injected knees, but small traces of tissue began to appear only 
from day 14 in their contralateral knees (Figures 5.9 and 5.10). 
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Unilateral intra-articular injections of FCA plus SP produced similar thickening of 
the synovial capsules compared with those of FCA injection alone (P=0.7758; two 
factor ANOVA; Figures 5.7 and 5.11C), but tissue thickening in the contralateral 
knees of the former group was more prominent (n二3, P<0.001, two factor ANOVA; 
Figures 5.8 and 5.11D). The differences were more obvious at day 1 and day 7 
(P<0.05 and 尸<0.001, respectively; Planned Contrasts). From the micrographs of 
Figures 5.9 and 5.10, the growth of synovial tissues on the menisci appeared much 
earlier (from day 1) in both test knees and contralateral knees of the FCA plus 
SP-treated groups compared with those of FCA-treated groups, which occurred on 
day 3 and day 14, respectively. 
�^d ^ r^irtila^e degradation 
As shown in the micrographs of Figure 5.12, unilateral intra-articular injections of 
FCA produced cartilage degradation from day 7 onwards; their contralateral knees 
were not affected (Figure 5.13). After unilateral intra-articular injections of FCA plus 
SP, the severity of the cartilage degradation over the 28 days was not significantly 
different to that of the FCA-treated group (n二3; P>0.05 for both test and contralateral 
knees; two factor ANOVA). However, subsequent analysis with Planned Contrast 
showed that SP produced significant cartilage degradation in the contralateral on day 
14(P<0.05;Figure5.14D). 
^ Rnne degradation 
The effect of unilateral intra-articular injections of FCA on bone degradation was 
similar to that on cartilage degradation; the onset of bone degradation appeared from 
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day 14 and their contralateral knees were again unaffected. With injection of FCA 
plus SP, the pattern on bone degradation was identical to that on cartilage 
degradation; signs of bone degradation were seen from day 14 in the test knees and 
no bone erosion in the contralateral knees. These results are shown in Figures 5.12, 
5.13 and 5.15. 
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Figure 5.1 
Comparison of levels of Evans blue extravasation in FCA-treated and FCA plus 
SP-treated rat knee joints. FCA-injected and FCA plus SP-injected knees both had 
significantly higher Evans blue extravasation than their saline-injected contralateral 
knees and saline-injected control knees (n二5-7; ***P<0.001; two factor ANOVA; 
Figures A and B). Moreover, when the contralateral (Figure D) and test knees 
(Figure C) between FCA-injected group and FCA plus SP injected group were 
compared, they both showed significant differences (n二5-7; ***P<0.001; two factor 
ANOVA). Significance levels of means calculated by Planned Contrasts are 
represented by #P<0.05 - ###P<0.001 for comparison of test knees with contralateral 
knees; +P<0.05 - +++P<0.001 for comparison of test knees with saline-injected 
control knees; °P<0.05 - for comparison between the test knees of the 
two groups; Ap<0.05 - aaap<0.001 for comparison between the contralateral knees 
between the two groups. 
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Figure 5.2 
Comparison of joint sizes in FCA-treated and FCA plus SP-treated rat knee joints. 
FCA-injected and FCA plus SP-injected knees both had significantly larger joint 
sizes than their saline-injected contralateral knees and saline-injected control knees 
(n二 17-28; ***P<0.001; two factor ANOVA; Figure A and B). There was no 
significant difference between FCA-injected and FCA plus SP-injected knees 
(P>0.05; two factor ANOVA, Figure C). However, when the contralateral 
saline-injected knees of FCA-injected group and FCA plus SP injected group were 
compared, the former group had larger joint sizes than the latter group (n=17-28; 
***尸<0.001; two factor ANOVA; Figure D). The symbols used for means comparison 
by Planned Contrasts are described in Figure 5.1. Data are shown as means士s.e.mean 
(shown by vertical bars) of the level of joint size. 
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Figure 5.3 
Comparison of levels of knee joint blood flow in FCA-treated and FCA plus 
SP-treated rat knee joints. Blood flow of FCA-injected knees was not significantly 
different to that of the saline-injected contralateral knees (n= 12-28; P>0.05; two 
factor ANOVA; Figure A and B). However, subsequent analysis by Planned 
Contrasts showed that FCA-injected knees had higher blood flow than their 
contralateral knees and control knees on day 7 (n=19-22; +P<0.05 and #P<0.05; 
Figure A). FCA plus SP-injected knees both had significantly higher blood flow than 
their saline-injected contralateral knees and saline-injected control knees (n= 13-20; 
***P<0.001; two factor ANOVA; Figure B). Moreover, when the contralateral 
(Figure D) and test knees (Figure C) of FCA-injected group and FCA plus SP 
injected group were compared, they both showed significant differences (n=5-7; 
***P<0.001; two factor ANOVA). The symbols used for the means comparison by 
Planned Contrasts are described in Figure 5.1. Data are shown as means土s.e.mean 
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Figure 5.4 
Accumulation of immune cells in the infrapatella fat pads of FCA-iiy ected (left 
column) and FCA plus SP-injected knees (right column)�The cell infiltration 
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Figure 5.5 
Accumulation of immune cells in the infrapatella fat pads in the contralateral knees of 
FCA-treated and FCA plus SP-treated animals�These contralateral knees received 
saline injections only. The cell density (blue dots) in the right column (FCA+SP) was 
higher than that in the left column (FCA alone). 
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Figure 5.6 
Comparison of levels of immune cell infiltration in synovial tissues of FCA-treated 
and FCA plus SP-treated rat knee joints. FCA-injected and FCA plus SP-injected 
knees both had significantly higher cell infiltration levels than their contralateral 
knees and the differences were obvious from day 3 onwards (n二3; ***尸<0.001; two 
factor ANOVA; #P<0.05 - ###P<0.001; Planned Contrasts; Figures A and B). The 
contralateral knees of FCA plus SP-treated groups had higher cell infiltration level 
than the contralateral knees of FCA-treated group and the changes were more 
obvious on day 1 (n二3，*P<0.05; two factor ANOVA; #P<0.05; Planned Contrasts; 
Figure D). The cell infiltration levels were not different between FCA-injected and 
FCA plus SP-injected knees (n=3; P>0.05, two factor ANOVA; Figure C). 
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Proliferation of synovial capsules in FCA-injected (left column) and FCA plus 
SP-injected (right column) knee joints. The spaces (S) between the menisci (M) 
and the bone (B) were similar between the two columns except on day 1; the FCA 
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Figure 5.8 
Proliferation of synovial capsules in the contralateral saline-injected knees of 
FCA-treated (left column) and FCA plus SP-treated (right column) animals. The 
spaces (S) between the menisci (M) and the bones (B) were narrower (occupied 
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Figure 5.9 
Proliferation of the synovial tissues on the menisci of FCA-injected (left column) 
and FCA plus SP-injected knee joints (right column)�In the FCA plus SP-injected 
knees, synovial tissue (S) proliferation appeared at the tips of menisci (M) from 
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Figure 5.10 
Proliferation of synovial tissues on the menisci of contralateral saline 
injected-knees of FCA-treated (left column) and FCA plus SP-treated (right 
column) animals. In the FCA plus SP-injected knees, growth of synovial tissues 
(S) appeared at the tips of the menisci (M) from day 1 onwards, whereas, they 
appeared from day 14 in the FCA-injected knees. 114 
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Figure 5.11 
Comparison of levels of synovial tissue proliferation of FCA-treated and FCA plus 
SP-treated rat knee joints. FCA-injected and FCA plus SP-injected knees both had 
more pronounced synovial tissue proliferation than their contralateral knees and 
progressed from day 3 onwards (n=3; ***尸<0.001; two factor ANOVA; #P<0.05 -
###P<0.001; Planned Contrasts; Figures A and B). The contralateral knees of FCA 
plus SP-treated groups had higher synovial tissue proliferation than the contralateral 
knees of FCA-treated group (n二3, ***P<0.001; two factor ANOVA; Figure D) and 
the effect was more obvious on day 1 and day 7 (#P<0.05 - ###P<0.001; Planned 
Contrasts). There was no significant difference between FCA-injected and FCA plus 
SP injected knees (n=3; P>0.05, two factor ANOVA; Figure C). 
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Figure 5.12 
Degradations of cartilage and bone in FCA-injected (left column) and FCA plus 
SP-injected knee joints (right column). In the FCA plus SP-injected knees, 
cartilage and bone degraded began on day 3，whereas, in FCA-injected knees, 
cartilage degradation appeared from day 7 onwards. 116 
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Figure 5.13 
Degradation of cartilage and bone in the contralateral saline-injected knees of 
FCA-treated (left column) and FCA plus SP treated (right column) animals. In 
the FCA plus SP treated-animals, cartilage and bone degradation appeared on 
day 7, whereas, in the FCA-treated animals, the cartilage and bone showed no 
erosion. 117 
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Figure 5.14 
Comparison of levels of cartilage degradation in FCA-treated and FCA plus 
SP-treated rat knee joints. FCA-injected and FCA plus SP-injected knees both had 
significantly higher cartilage degradation levels than their contralateral knees from 
day 7 onwards (n二3; ***P<0.001; two factor ANOVA; Figures A and B; #•尸<0.001 
Planned Contrasts). However, when the contralateral knees and the test knees 
between FCA-treated and FCA-treated plus SP-treated groups were compared, there 
was no significant difference (n二3; P=0.7748; P=0.5387, respectively; two factor 
ANOVA; Figure C and D). However subsequent analysis by Planned Contrasts 
showed that the contralateral knees of the FCA plus SP group had higher cartilage 
degradation level than that of the FCA-treated group on day 14 (#P<0.05). 
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Figure 5.15 
Comparison of levels of bone erosion in FCA-treated and FCA plus SP-treated rat 
knee joints. FCA-injected and FCA plus SP-injected knees both had significantly 
higher bone erosion levels than their contralateral knees and the onset time were both 
at day 14 (n=3; ***P<0.001 for both; two factor ANOVA;漏PO.QQl; Planned 
Contrast; Figures A and B). However, when the contralateral knees and the test knees 
between FCA-treated and FCA plus SP-treated groups were compared, there was no 
significant difference (n=3, *P>0.05; two factor ANOVA; Figures C & D). 
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5.4 Discussion 
The present model of monoarthritis is characterized by signs of plasma protein 
extravasation, vasodilatation, joint swelling, immune cell infiltration, synovial tissue 
proliferation, and cartilage and bone degradation in the test knee; there is minimal or 
absence of these signs in the contralateral knee. On the other hand, injection of 
Inmol SP in addition to FCA exacerbated some of these signs, which to a smaller 
extent, were also detected in the contralateral knee. These results are consistent with 
the view that SP plays an important role in the development of arthritis. 
The dose of SP used in this study was 1 nmol because this dose produced the most 
pronounced and transient ( � 2 mins) vasodilator response without affecting the 
systemic circulation. Above this dose, SP caused a drop in systemic blood pressure 
and produced salivation in the animal (data not shown). When Inmol of SP was 
injected intra-articularly into rat knee joints without FCA treatment, there was no 
plasma extravasation, joint swelling or vasodilatation at 4 hours after the SP injection 
(data not shown). Thus, the enhancement effects of SP on FCA-induced Evans blue 
extravasation, vasodilatation, immune cell infiltration, synovial tissue proliferation 
and cartilage degradation was not a result of simple additive effects of the two 
agents. 
SP has been shown to induce endothelial gap opening and thereby causes increased 
leakage of the blood vessels via the activation ofNKi receptors (Baluk et al., 1997; 
Lam & Ferrell, 1993b; Lam & Wong, 1996), which are upregulated during 
inflammation (Sakai et al, 1998). The activation of vascular NKi and possibly NK2 
receptors by SP also results in vasodilatation (Lam & Ferrell, 1993a; Lam & Wong, 
1996). Therefore, it is not surprising to find that SP augmented plasma protein 
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extravasation and basal blood flow in the knee joints of the adjuvant-treated rats. 
Interestingly, SP was found to increase basal blood flow bilaterally in the knee joints 
of the adjuvant-treated rats throughout the 28 days. It potentiated and extended the 
Evans blue extravasation response in the FCA-treated knee from 1 week to 2 weeks, 
and although the potentiating effect was less in the contralateral knee, it was 
observable throughout the 28 days. On the other hand, SP augmented joint swelling 
in the FCA-treated knee on day 7 only and this response was absent in the 
contralateral knee. Moreover, SP had no effect on the histological signs in the 
FCA-treated knees. On the other hand, the onset of these signs was accelerated in the 
contralateral knees, which became more apparent in the first 2 weeks, except that 
there was still no sign of bone degradation. Clearly, these results showed that the 
time course of effects of SP on the various inflammatory parameters are different. 
These differences are unlikely to be due to down regulation or desensitization of TK 
receptors or that there was increased synthesis of peptide degrading enzymes during 
the late stage of the disease, since the occurrence of these events would also reduce 
the action of SP on basal blood flow. Moreover, as mentioned above, TK receptors 
are expected to be upregulated during inflammation (Sakai et al., 1998), which is in 
disagreement with the suggestion. 
It should be noted that FCA-induced Evans blue extravasation was not sustained 
beyond 7 days. This may indicate that there is a self-limiting factor for the response, 
perhaps due to remodeling of the structural architect of the blood vessels in the 
chronically inflamed knee. Hence, as a result of the vascular remodeling (which can 
be confirmed by testing the Evans blue extravasation response to non-tachykinin 
agents), the addition of SP could maximally extend the response to day 14 only. On 
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the other hand, the contralateral knee, which is less inflamed and thus is less affected 
by the vascular remodeling, it can respond to SP with augmented Evans blue 
extravasation throughout the 28 days. Assuming that this hypothesis is correct, and 
taking into consideration that SP-induced vasodilatation was observable throughout 
the 28 days, this would suggest that vascular remodeling affects only the 
permeability of the blood vessels and not its response to vasodilator agents. 
In addition to its direct action on the joint microvasculature, SP has been shown to 
cause the release of IL-1 and TNFa from macrophages, which among other actions, 
can upregulate the expression of adhesion molecules by endothelial cells (Lotz et aL, 
1988). SP also has chemotactic action on monocytes, neutrophils and eosinophils 
(Eglezos et al., 1991; Lotz et al, 1988); the former of which possesses NK2 receptors 
that can be activated to release inflammatory cytokines (Bmnelleschi et al., 1998). 
SP and capsaicin were shown to enhance collagenase release from human 
synoviocytes and stimulate their proliferation (Lotz et al., 1987; Matucci-Cerinic et 
al., 1990). Besides synoviocytes (type-B cell in synovium), SP activates type-A 
cells (macrophage-like cells) to produce oxygen-free radicals, and this is susceptible 
to inhibition by NKi receptor antagonist (Tanabe et aL, 1996). SP has also been 
shown to reduce synthesis of proteoglycan that could unbalance matrix formation in 
the cartilage and cause degradation of the tissue (Decaris et al., 1999). 
However, the present study showed that SP had minimal or no effect on the severity 
and the onset of joint swelling, immune cell accumulation, synovial tissue 
proliferation, and cartilage degradation in the FCA-treated knees. This may indicate 
that mediators other than SP are important in producing these inflammatory signs or 
that SP has only a minor role in producing these signs. On the other hand, SP 
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accelerated the onset of immune cell accumulation, synovial tissue proliferation, and 
cartilage degradation in the contralateral joints. This would suggest that SP 
participates in the initiation of these responses, possibly by recruitment of other 
inflammatory mediators, the actions of which eventually overwhelm the SP effect. 
There was no bone degradation observed in all the contralateral knees in the present 
study. This is suspected to be due to the contralateral knees being less inflamed than 
the FCA-treated knees, and since bone damage usually occurs at the late stage of 
arthritis when the disease is more severe, it is therefore not possible to observe bone 
damage in the contralateral knees within the 28 days of the experiment. 
Symmetrical joint involvement is a common feature of rheumatoid arthritis. This was 
hypothesized to be due to “ neurogenic switching"; a phenomenon that describes the 
occurrence of inflammation in one site, and by a neurogenic pathway causes 
inflammation at another site (Meggs, 1995). The event is thought to involve the 
activation of nociceptors in peipheral sensory neurones by a noxious or inflammatory 
stimulus. This triggers impulses that carry the pain messages to the spinal cord and 
are subsequently relayed to the higher centres of the brain. In the spinal cord or even 
at the higher centres of the brain, some of these impulses may be redirected to other 
locations in the periphery to cause the release of pro-inflammatory neuropeptides. 
Thus, inflammatory processes can be initiated at sites distal to the initial stimulus. 
The above hypothesis is supported by several experimental findings. For example, 
systemic administration of adjuvant in rats resulted in symmetrical arthritis, but in 
animals with unilateral nerve section, the arthritis was delayed in onset and 
diminished in severity in the denervated side compared with the intact side 
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(Courtright & Kuzell，1965; Levine et al., 1985). Spinal cord compression also 
abolished contralateral cartilage degradation in rat adjuvant-induced arthritis model 
(Decaris et al., 1999). Moreover, a clinical report suggests that hemiparesis 
minimizes arthritic manifestations on the affected side (Smith, 1979). 
Systemic administration of adjuvant in rats is a popular model of polyarthritis that 
resembles that human disease. Other arthritis models that are produced by 
monoarthricular injections of inflammatory chemicals/mediators also evoked arthritis 
in multiple joints. For example, unilateral injections of crystal into the rat foodtpad 
produced symmetrical swelling of both foodpads (Denko CW, 1978). Macrophages 
and SP levels were increased bilaterally after induction of monoarthritis in the rat 
knee joint by latex sphere (Kidd et al., 1995). Injury applied to one hindpaw of the 
rat produced hyperalgesia in both limbs (Levine et al, 1985). In contrast, a recent 
study by Dowed and co-workers (1998) showed that unilateral intra-articular 
injection of a small dose of FCA in the rat knee joint produced arthritis only in the 
treated knee. This observation was confirmed by the present study that showed 
vascular and histological changes were confined to the FCA-treated knee, indicating 
that it is a good monoarthritis model. 
The present study showed that when SP was injected into the arthritic rat knee joint, 
it promoted the spread of the arthritis to the contralateral knee. SP has relatively short 
half-life in the circulation (Scott et al, 1991), and thus it is unlikely that systemic 
absorption of SP could account for the contralateral effects. Nevertheless, it might be 
that SP could release other pro-inflammatory mediators that are more stable in the 
circulation, and these could be transported to the other side in sufficient 
concentrations to produce the contralateral effects. On the other hand, a more 
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plausible explanation would be that SP produced the contralateral effects by acting 
on the sensory nerve terminals to initiate the events of neurogenic switching 
described above. The exact mechanisms for the contralateral effects of SP remain to 
be detennined. Nevertheless, SP is confirmed to be an important mediator in the 
development of the present animal model of arthritis. Therefore，it is speculated that 
antagonists of SP would be beneficial to the control of arthritis. This hypothesis is 
investigated in the following sections, 
rnnclusions 
The present study demonstrated that SP accelerated the onset of certain signs 
adjuvant- induced arthritis in the rat. It also caused spreading of the disease to the 
contralateral otherwise, relatively normal knee joint These results confirmed that SP 
is an important mediator of arthritis, and that it plays a pivotal role in the spreading 
of the disease to other joints. The findings also implicate that antagonists of SP could 
be of value in the treatment of arthritis. 
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Chapter 6 
F 件… . f t . . h y k i n i n r e c 中阶训 t a 卯 n i s t s on F r A - i n d i i c e d arthritis 
^^ ^ Tntroduction 
From the previous chapter, substance P (SP) was shown to be an important mediator 
of arthritis that promotes the spreading and accelerates the onset of the disease. Thus, 
it was found to enhance vasodilatation and plasma extravasation in the FCA-induced 
monoarthritis model. Furthermore, SP caused the vascular and histological signs of 
arthritis to appear in the contralateral, otherwise, relatively normal knee joint These 
results implicate that the inhibition of SP actions may provide a novel approach in 
the treatment of arthritis. 
One of the methods of inhibiting SP (and other tachykinins) actions is by the use of 
the neurotoxin capsaicin. In adult rats, long-term exposure of sensory neurones to 
capsaicin caused depletion of SP and other neuropeptides in the sensory nerve 
terminal (Gamse et aL, 1981; Maggi et al., 1987). In neonatal rats，the same 
treatment with capsaicin produced degeneration of the sensory fibres (Jancso & 
Kiraly, 1981). Hence, capsaicin acting via either or both of these mechanisms could 
prevent the contribution of SP to the arthritis process. Clinically, treatments of 
capsaicin have been shown to provide certain degrees of pain relief in patients with 
arthritis and skin conditions (Niv & Gur Aryeh, 1996; Rumsfield & West, 1991). 
However, the initial stinging or burning sensation caused by the application of 
capsaicin was not well tolerated by these patients (Rains & Bryson，1995). 
A more traditional method of inhibiting SP actions is by the use of receptor 
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antagonists. As mentioned in the "Introduction" section in chapter 1, SP produces 
biological actions via interaction with three major tachykinin receptor types, the NK1, 
NK2 and NK3 receptors, but it has stronger preference for the NKI receptors. In 
recent years, selective antagonists for each of these tachykinin receptor types have 
been developed. The NKI receptor antagonist has already been shown to have 
anti-inflammatory actions in a rat model of colitis (Stucchi et aI., 2000). In this 
chapter, the anti-inflammatory efficacies of several tachykinin receptor antagonists 
were investigated on the adjuvant-induced monoarthritis model. 
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6.2 Method 
“ 71 Tntrflvenous NKi recentor antagonists on FCA-induced arthritis 
Three NKi receptor antagonists SR140333, RP67580 and CP99994 were tested on 
FCA-induced arthritis. SD rats were anaesthetized with urethane (2g/kg) and only 
one dose of one of the above antagonists was tested on each rat. The antagonists 
were administered intravenously via the jugular vein 20 minutes before unilateral 
intra-articular injection of FCA to induce monoarthritis; the other knee was injected 
with 0.1ml physiological saline to act as control. After 24 hours, changes in vascular 
permeability and knee joint swelling were determined by Evans blue extravasation 
and a digital micrometer, respectively. 
6 T n t r a p e r i t o n e a l tachykinin recentor antagonists on FCA-induced arthritis 
Repetitive injections of tachykinin receptor antagonists are required in order to assess 
their influence on long term changes induced by FCA. Hence, for convenience, in 
this part of the study, the antagonists were administered by intraperitoneal injections. 
The selective antagonists for NKi, NK2, and NK3 receptors used were SR140333, 
SR48968 and SR142801, respectively (Edmond-Alt et al., 1993; Edmond-Alt et al., 
1992； Emonds-Alt et aL, 1995). These antagonists (1.2mg/kg) were administered 
alone or in combination (for NKi and NK2 antagonists) 20 minutes prior to the 
induction of arthritis; thereafter the same dose(s) of the antagonists were 
administered once daily. For the assessment of Evans blue extravasation and joint 
swelling, the rats were treated with the antagonists for 1 to 7 days, and for 
assessment of histological changes, the treatment period was 1 to 28 days. Another 
group of animals acted as controls, received daily intraperitoneal injection of 0.1ml 
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saline instead of the antagonists. 
6.3 Results 
6.31 Intravenous NKi receptor antagonists on FCA-induced Evans blue 
extravasation and joint swelling 
As shown in Figure 6.1 A, intravenous administration of O.lmg/kg of the NKi 
receptor antagonists SR140333 or RP67580 suppressed the Evans blue extravasation 
response to FCA (n二4-5; P<0.05 for both; Student's unpaired Mest), but the other 
NKi receptor antagonist CP99994 (Img/kg and 6mg/kg) produced no change (n=4; 
p>0.05; Student's unpaired Mest). With these doses, none of the antagonists affected 
the FCA-induced joint swelling (n=17-23; P>0.05; Student's unpaired Mest; Figure 
6.1B) 
6.32 Intraperitoneal tachykinin receptor antagonists on FCA-induced Evans 
blue extravasation and joint swelling 
Higher doses of SR140333 were tested intraperitoneally. It produced significant 
suppression of Evans blue extravasation at doses of 0.6mg/kg to 2.4mg/kg (n=4-5; 
尸<0.01 _ 尸<0.001; One factor ANOVA; Planned Contrasts; Figure 6.2A); the level of 
inhibition was already maximum at 0.6mg/kg. However, it reduced joint swelling 
only at doses of O.lmg/kg and 1.2mg/kg (n=17-23; P<0.05-0.01; One factor ANOVA; 
Planned Contrasts; Figure 6.2B). 
As shown in Figure 6.3, intraperitoneal administration of 1.2mg/kg of either the NKi 
receptor antagonist SR140333 or the NK! receptor antagonist SR84968 produced 
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significant inhibition on Evans blue extravasation from day 1 to day 7 (n=4-6; 
P<0.001; PO.Ol, respectively; two factor ANOVA). However, there was no 
significant suppression on Evans blue extravasation with the co-administration of 
SR140333 and SR48968 (n=4-5; P=0.0547; two factor ANOVA). When analyzed by 
Planned Contrasts, there was significant suppression of Evans blue extravasation on 
day 1 (n=5;户<0.05). The NK3 receptor antagonist, SR142801 (1.2mg/kg) inhibited 
Evans blue extravasation but not joint size on day 1 post induction of the arthritis 
(n=5,户<0.05, Student's unpaired West). Either individual injections of SR140333 
and SR48968 or co-administration of the two antagonists inhibited the joint swelling 
(n=13-30; P<0.05-0.01; two factor ANOVA; Figure 6.4). Co-administration of the 
two antagonists produced less suppression than that produced by SRI40333 alone 
(P<0.05, two factor ANOVA, Figure 6.4) 
6.33 Intraperitoneal tachykinin receptor antagonists on FCA-induced immune 
cell accumulation 
The effects of intraperitoneally administered NKi receptor antagonist SR140333 
(1.2mg/kg/day) on immune cell accumulation in the infra-patella fat pads of arthritic 
rats are illustrated in Figures 6.5, 6.6 and 6.11. Compared with the control animals, 
SRI40333 significantly suppressed immune cell accumulation in the FCA-injected 
knees and this effect was most obvious at day 28 (n=3; P<0.05 for both; two factor 
ANOVA; Planned Contrasts); it had no effect on the contralateral saline-injected 
knees (n=3; P>0.05; two factor ANOVA). On the other hand, the NK2 receptor 
antagonist SR48968 produced no change on either the test or contralateral knees 
(n=3; P>0.05; two factor ANOVA; Figures 6.7, 6.8 and 6.11). Co-administration of 
SR140333 and SR48968 also did not affect immune cell accumulation in the test or 
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contralateral knees (n=3; P>0.05 for both; two factor ANOVA; Figure 6.9, 6.10 and 
6.11). 
6.34 Intraperitoneal tachykinin receptor antagonists on FCA-induced synovial 
tissue proliferation 
Compared with the control animals, SR140333 (1.2mg/kg/day) significantly reduced 
synovial tissue proliferation on FCA-injected test knees (n=3;尸<0.05; two factor 
ANOVA; Figures 6.12 and 6.18A), but not on those of the contralateral 
saline-injected knees (n二3; P>0.05; two factor ANOVA; Figures 6.13 and 6.18B). 
Suppression on the test knees was more obvious on day 14 (P<0.05; Planned 
contrasts). Similarly, SR48968 (1.2mg/kg/day) significantly reduced synovial tissue 
proliferation on FCA-injected test knees (n=3; P<0.05; two factor ANOVA; Figures 
6.14 and 6.18A), but not on those in the contralateral saline-injected knees (n=3; 
尸>0.05; two factor ANOVA; Figures 6.15 and 6.18B). Again, suppression on the test 
knees was most obvious on day 7 and day 14 (尸<0.05; P<0.01, respectively; Planned 
Contrasts). However, co-administration of SR140333 and SR48968 did not affect 
synovial tissue proliferation on either the test or contralateral knees (n=3; P>0.05 for 
both; two factor ANOVA; Figure 6.16, 6.17 and 6.18), except on day 14, suppression 
on the test knees was significant (P<0.05; Planned Contrasts). 
6.35 Intraperitoneal tachykinin receptor antagonists on FCA-induced cartilage 
degradation and bone erosion 
Compared with the control animals, SR140333 (1.2mg/kg/day) significantly reduced 
cartilage degradation and bone erosion in the FCA-injected test knees (n=3; P<0.05 
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and P<0.01, respectively; two factor ANOVA; Figures 6.19, 6.25A and 6.26A). The 
suppression was most obvious on day 14 and day 28 (尸<0.001 and iMXOl, 
respectively; Planned Contrasts). On the other hand, SR48968 (1.2mg/kg/day) 
produced no change on cartilage degradation and bone erosion in the test knees (n二3; 
P>0.05; two factor ANOVA; Figures 6.21, 6.25A and 6.26A). Co-administration of 
SRI40333 and SR48968 enhanced cartilage degradation in the test knees (n=3; 
尸<0.05; two factor ANOVA; Figures 6.23 & 6.25A) which was most prominent on 
day 7 and day 14 (n二3; PO.OOl and PO.Ol, respectively; Planned Contrasts), 
whereas, bone erosion was enhanced only on day 3 (n=3; P<0.001, Planned 
Contrasts). There was no cartilage degradation or bone erosion in the contralateral 
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Figure 6.1 
Intravenously administered NKi receptor antagonists on (A) Evans blue 
extravasation and (B) joint swelling on day 1 post induction of arthritis by FCA. 
SR140333 (O.lmg/kg) and RP67580 (O.lm/kg) both suppressed FCA-induced Evans 
blue extravasation (n=4-5, *P<0.05 for both; Student's unpaired Mest), whereas, 
CP99994 (Img/kg and 6mg/kg) had no effect (n=4; F>0.05; Student's unpaired 
Mest). None of the antagonists produced a change on joint swelling (n= 17-23; 
P>0.05; Student's unpaired t-test). Data are shown as means 士s.e.mean (shown by 
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Figure 6.2 
Intra-peritoneally administered SRI 40333 on (A) Evans blue extravasation & (B) 
joint swelling on day 1 post induction of arthritis by FCA. SR140333 (>0.6mg/kg) 
produced significant suppression of Evans blue extravasation (n=4-5; ** 尸<0.01, *** 
PO.OOl; One Factor ANOVA, Planned Contrasts). However, it reduced joint 
swelling only at the dose of O.lmg/kg and 1.2mg/kg (n=17-23; *尸<0.05，** P<0.01; 
One Factor ANOVA, Planned Contrasts). Data are shown as means 士s.e.mean 
(shown by the vertical bars) of differences between FCA-injected and contralateral 
saline-injected knees. 
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Figure 6.3 
Individual and co-administration of tachykinin antagonists (1.2mg/kg/day) on Evans 
blue extravasation in FCA-induced arthritic rat knee joints. Compared with saline 
injection, individual administration of the NKi receptor antagonist SR140333 (NKi) 
and the NK2 receptor antagonist SR48968 (NK2) both suppressed Evans blue 
extravasation (n=4-6; ***P<0.001; two factor ANOVA). The former antagonist 
reduced Evan blue extravasation on day 1 and day 7 while the latter reduced Evans 
blue extravasation on day 1 only (##P<0.01, ###P<0.001; Planned Contrasts). 
Co-administration of these two antagonists (NK1NK2) had no inhibitory effect on 
Evans blue extravasation (n=4-6;尸〉0.05; two factor ANOVA), except on day 1 (n=5; 
#P<0.05; Planned Contrasts). The NK3 receptor antagonist SR142801 (1.2mg/kg; 
NK3) significantly reduced Evans blue extravasation on day 1 compared with saline 
on that day (n=4; *尸<0.05; Student's unpaired -test). 
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Figure 6.4 
Individual and co-administration of tachykinin antagonists (1.2mg/kg/day) on joint 
swelling in FCA-induced arthritic rat knees. Compared with saline injection, 
individual administration of the NKi receptor antagonist SR140333 (NKi), the NK2 
receptor antagonist SR48968 (NK2) and co-administration of these two antagonists 
(NK1NK2) all suppressed joint swelling (n=13-30; **尸<0.01; *P<0.05; *尸<0.05, 
respectively; two factor ANOVA). SR140333 and SR48968 suppressed the joint 
swelling on day 1 and day 3, respectively (#P<0.05; Planned Contrasts). 
Co-administration of these two antagonists (NK1NK2) had smaller inhibitory effect 
on joint swelling than the NKi receptor antagonist alone (*P<0.05; two factor 
ANOVA). Data are shown as means 土s.e.mean (shown by the vertical bars) of 
differences between FCA-injected and contralateral saline-injected knees. 
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Figure 6.5 
NKi receptor antagonist SR140333 on immune cell accumulation in the 
infrapetella fat pads of the test rat knee injected with FCA. SR140333 (right 
column) was administered intraperitoneally at a dose of 1.2mg/kg/day, and control 
animals (left column) received daily injection of 0.1ml saline instead. Immune cell 
accumulation was less pronounced in the SR140333 treated animals. 
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Figure 6.6 
NKi receptor antagonist SR140333 on immune cell accumulation in the 
infrapetella fat pads of the contralateral rat knee injected with saline. SRI40333 
(right column) was administered intraperitoneally at a dose of 1.2mg/kg/day, and 
control animals (left column) received daily injection of 0.1ml saline instead. 
Immune cell accumulation was similar in both groups. 
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Figure 6.7 
NK2 receptor antagonist SR48968 on immune cell accumulation in the infrapetella 
fat pads of the test rat knees injected with FCA. SR48968 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injection of 0.1ml saline instead. Immune cell 
accumulation was similar in both groups. 
139 
Contralateral Contralateral 
Saline (i.p.) SR140333 (i.p.) 
m-m 
_ - _ 
m - _ 
m - • 
Figure 6.8 
NK2 receptor antagonist SR48968 on immune cell accumulation in the infrapetella 
fat pads of the contralateral rat knees injected with saline. SR48968 (right column) 
was administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals 
(left column) received daily injection of 0.1ml saline instead. Immune cell 
accumulation was similar in both groups. 140 
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Figure 6.9 
Co-administration of SR140333 and SR48968 on immune cell accumulation in the 
infrapetella fat pads of the test rat knees injected with FCA The two antagonists 
(right column) were administered intraperitoneally at a dose of 1.2mg/kg/day, and 
control animals (left column) received daily injection of 0.1ml saline instead. 
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Figure 6.10 
Co-administration of SR140333 and SR48968 on immune cell accumulation in the 
intrapatella fat pads of the contralateral rat knees injected with saline. The two 
antagonists (right column) were co-injected intraperitoneally at a dose of 
1.2mg/kg/day, and control animals (left column) received daily injections of 0.1ml 
saline instead. Immune cell accumulation was similar in both groups. 
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Figure 6.11 
Intraperitoneally administered tachykinin receptor antagonists on immune cell 
accumulation in synovial tissues of (A) test rat knee joints injected with FCA, and (B) 
the contralateral knee joints injected with saline. Antagonists were administered at a 
dose of 1.2mg/kg/day, and the control animals received daily intraperitoneal 
injections of 0.1ml saline instead. Compared with the FCA-injected test knees of 
control animals, the NKi receptor antagonist SR140333 produced significant 
suppression on immune cell accumulation in the test knees and this suppressive 
effect was most pronounced on day 28 (n=3, *P<0.05; two factor ANOVA; #P<0.05; 
Planned Contrasts). However, the NK! receptor antagonist SR48968 administered 
alone or in combination with SR140333 produced no change (n=3, P>0.05; two 
factor ANOVA). Compared with the contralateral saline-injected knees of control 
animals, administration of these antagonists alone or in combination did not affect 
the level of immune cell accumulation in the contralateral knees (n=3, P>0.05; two 
factor ANOVA). Data are shown as means士s.e.mean (shown by the vertical bars) of 
the level of cell infiltration graded by the criteria described in the "Methodology" 
section in chapter 3. 
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Figure 6.12 
NKi receptor antagonist SRI40333 on synovial tissue proliferation on menisci of 
the test rat knee joints injected with FCA. SR140333 (right column) was 
administered intrapeiitoneally at a dose of L2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Synovial tissue 
proliferation was much less pronounced in the SR140333 treated group. 
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Figure 6.13 
NKi receptor antagonist SR140333 on synovial tissue -proliferation on menisci of 
the contralateral rat knee joints injected with saline�SRI40333 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Synovial tissue 
proliferation was similar in both groups. 
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Figure 6.14 
NK2 receptor antagonist SR48958 on synovial tissue proliferation on menisci of 
the test rat knee joints injected with FCA. SR48968 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Synovial tissue 
proliferation was much less pronounced in the SR48968 treated group. 
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Figure 6.15 
NK2 receptor antagonist SR48968 on synovial tissue proliferation on menisci of 
the contralateral rat knee joints injected with FCA. SR48968 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Synovial tissue 
proliferation was similar in both groups. 147 
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Figure 6.16 
Co-administration of SR140333 and SR48968 on synovial tissue proliferation on 
menisci of the test rat knee joints injected with FCA. The two antagonists (right 
column) were co-injected intraperitoneally at a dose of 1.2mg/kg/day, and control 
animals (left column) received daily injections of 0.1ml saline instead. Synovial 
tissue proliferation was similar between two groups. 148 
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Figure 6.17 
Co-administration of SR140333 and SR48968 on synovial tissue proliferation on 
menisci of the contralateral rat knee joints injected with sal ine�The two 
antagonists (right column) were co-injected intraperitoneally at a dose of 
1.2mg/kg/day, and control animals (left column) received daily injections of 0.1ml 
saline instead. Synovial tissue proliferation was similar in both groups. 
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Figure 6.18 
Intraperitoneally administered tachykinin receptor antagonists on synovial tissue 
proliferation in (A) test rat knee joints injected with FCA, and (B) the contralateral 
knee joints injected with saline. Compared with the FCA-injected test knees of 
control animals, administration of 1.2mg/kg/day of SR140333 or SR48968 produced 
significant suppression on synovial tissue proliferation in the test knees (n=3; 
*P<0.05; two factor ANOVA). This effect was most obvious on day 14 for the former 
antagonist, and on days 7 and 14 for the latter antagonist (#P<0.05; Planned 
Contrasts). However, co-administration of the two antagonists produced no change 
(n=3, P>0.05; two factor ANOVA), except at day 14 (#P<0.05; Planned Contrasts). 
Compared with the contralateral saline-injected knees of control animals, 
administration of these antagonists alone or in combination did not affect synovial 
tissue proliferation in the contralateral knees (n=3; P>0.05; two factor ANOVA). 
Data are shown as means土s.e.mean (shown by the vertical bars) of the level of 
synovial tissue proliferation graded by the criteria described in the "Methodology" 
section in chapter 3. 
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Figure 6.19 
NKi receptor antagonist SR140333 on cartilage degradation and bone erosion of 
the test rat knee joints injected with FCA. SR140333 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Cartilage degradation 
and bone erosion were much less pronounced in the SR140333 treated group. 
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Figure 6.20 
NKi receptor antagonist SR140333 on cartilage degradation and bone erosion of 
the contralateral rat knee joints injected with saline. SR140333 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Cartilage degradation 
and bone erosion were similar in both groups. 
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Figure 6.21 
NK2 receptor antagonist SR48968 on cartilage degradation and bone erosion of the 
test rat knee joints injected with FCA�SR48968 (right column) was administered 
intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left column) 
received daily injections of 0.1ml saline instead. Cartilage degradation and bone 
erosion were similar in both groups. 
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Figure 6.22 
服 2 receptor antagonist SR48968 on cartilage degradation and bone erosion of the 
contralateral rat knee joints injected with saline. SR48968 (right column) was 
administered intraperitoneally at a dose of 1.2mg/kg/day, and control animals (left 
column) received daily injections of 0.1ml saline instead. Cartilage degradation and bone erosion were similar in both groups. 
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Figure 6.23 
Co-administration of SR140333 and SR48968 on cartilage degradation and bone 
erosion of the test rat knee joints injected with FCA. The two antagonists (right 
coluiim) were co-injected intraperitoneally at a dose of 1.2mg/kg/day, and control 
animals (left column) received daily injections of 0.1ml saline instead. Cartilage 










Co-administration of SR140333 and SR48968 on cartilage degradation and bone 
erosion of the contralateral rat knee joints injected with saline. The two antagonists 
(right column) were co-injected intraperitoneally at a dose of L2mg/kg/day, and 
control animals (left column) received daily injections of 0.1ml saline instead. 
Cartilage degradation and bone erosion were similar in both groups. 
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Figure 6.25 
Intraperitoneally administered tachykinin receptor antagonists on cartilage 
degradation in (A) the test knees injected with FCA, and (B) the contralateral knee 
joints injected with saline. Compared with the FCA-injected test knees of control 
animals, administration of 1.2mg/kg/day of SR140333 produced significant 
suppression on cartilage degradation in the test knees. This inhibition was most 
obvious on day 7 and day 28 (n=3; *尸<0.05; two factor ANOVA; ##P<0.01; 
###P<0.001, respectively; Planned Contrasts). However, SR48968 administration 
alone produced no change (n=3, P>0.05; two factor ANOVA). Co-administration of 
the two antagonists enhanced cartilage degradation, and this was most obvious on 
day 7 and day 14 (n=3; *P<0.05; two factor ANOVA; ##P<0.001; ###P<0.001, 
respectively; Planned Contrasts). There was no cartilage degradation in the 
contralateral saline-injected knees of all animals. Data are shown as means土s.e.mean 
(shown by the vertical bars) of the level of cartilage degradation graded by the 
criteria described in "Methodology" section in chapter 3. 
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Figure 6.26 
Intraperitoneally administered tachykinin receptor antagonists on bone erosion in (A) 
the test knees injected with FCA, and (B) the contralateral knee joints injected with 
saline. Compared with the FCA-injected test knees of control animals, administration 
of 1.2mg/kg/day of SR140333 produced significant suppression on bone erosion in 
the test knees (n=3; *P<0.05; two factor ANOVA). The suppression was more 
obvious from day 14 onwards (##P<0.01; Planned Contrasts). However, SR48968 
administration alone or in combination of SR140333 produced no change (n二3， 
p>0.05; two factor ANOVA), except the latter treatment had enhanced bone erosion 
on day 7 compared with the control group (n二3; ###P<0.001; Planned Contrasts). 
There was no bone erosion in the contralateral saline-injected knees of all animals. 
Data are shown as means土s.e.mean (shown by the vertical bars) of the level of bone 
erosion graded by the criteria described in the "Methodology" section in chapter 3. 
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6.4 Discussion 
Amann and co-workers (1995) showed that intravenous injection of O.lmg/kg 
SRI 40333 produced almost complete inhibition of mustard oil-induced plasma 
extravasation after 20 minutes, and this effect was still significant 24 hours after 
administration. However, the inhibition produced by subcutaneous administration of 
SRI40333 could not last for 24 hours until the dose reaches Img/kg. Thus, in this 
study, tachykinin antagonists were administered by the i.v. route. 
Three tachykinin NKi receptor antagonists SR140333, RP67580 and CP99994 were 
tested for their efficacies in reducing Evans blue extravasation and joint swelling in 
the present rat model of monoarthritis induced by FCA. By intravenous 
administration, SR140333 was more potent than RP67580, and CP99994 was 
ineffective in reducing Evans blue extravasation. These results support the view that 
there are species variants ofNKi receptors, and are in line with the relative inhibitory 
potencies of the three antagonists on rat NKi receptors, which for SRI40333, 
RP67580 and CP99994 were reported to have Ki (nM) values of 0.027, 4 and 136, 
respectively (Saria, 1999). Another reason for the lack of efficacy of CP99994 could 
be due to its labile chemical structure; being susceptible to demethylation of the 
methoxy group on the phenyl ring of the benzylamine side chain (Rosen et al., 1998). 
The short duration of the action of CP99994 has also been reported by Rupniak and 
co-workers (1997). The present study confirmed that SR140333 is the most potent 
antagonist on rat NKi receptors. 
SP is the preferential endogenous agonist for NKi receptors, but it may also act on 
other tachykinin receptor types (Burcher et al., 1991; Mussap et al., 1993). Selective 
antagonists for each of the tachykinin receptor types now exist; they include 
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SR140333, SR48968 and SR142801, which are selective antagonists for NKi, NK2 
and NK3 receptors, respectively. These antagonists were employed in the present 
study to determine the involvement of the different tachykinin receptor types in the 
development of arthritis. Daily intravenous injections of these antagonists are 
required in order to assess their effects on long-term changes in the arthritic animals. 
Using doses of 1.2mg/kg/day, SR140333 was found to be the most potent antagonist 
in reducing Evans blue extravasation and joint swelling in the arthritic rats. 
SRI42801 was the least efficacious and it did not affect joint swelling. This finding 
indicates an insignificant contribution ofNKs receptors in FCA-induced arthritis. 
SRI40333 was effective in reducing all the histological changes in the arthritic rat 
knee joint that include immune cell infiltration, synovial tissue proliferation, 
cartilage degradation and bone erosion. SR48968 reduced synovial tissue 
proliferation only, and SRI42801 was not tested on the histological changes due to 
its lack of efficacy in reducing joint swelling. These findings support the notion that 
NKi receptors are of greater importance than the other tachykinin receptor types in 
mediating the development of the arthritis symptoms. The contralateral knee joints of 
the present monoarthritis model had no sign or minor arthritis symptoms. Hence, it is 
not possible to determine whether the antagonists could exert bilateral inhibition in 
the present model. 
SR48968, at a dose of 2nmol (compared to 2)amol used in this study) produced more 
than 18 hours of inhibition of faecal output stimulated by a selective NK2 agonist 
(Croci et al., 1994). It also has a pAi value of 8.31 on rat vas deferens preparations 
(Edmond-Alt et al, 1992). Therefore, the low antagonist potency of SR48968 in the 
present study is unlikely to that due to fast metabolism of the drug or the lack of 
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specificity of the antagonist to rat tachykinin receptors. It is more probable that the 
findings indicate a lesser contribution of NKi receptors to the development of 
FCA-induced arthritis in the rat. 
Interestingly, co-administration of SR140333 and SR48968 did not produce additive 
or synergistic suppression of the arthritic symptoms. Moreover, the inhibition was 
often less than that produced by either of the two antagonists administered alone. In 
the case of cartilage degradation and bone erosion, co-administration of SRI 40333 
and SR48968 even worsens the conditions. If SR140333 and SR48968 were 
producing inhibition by blocking their respective NKi and NK2 receptors, then 
co-administration of the two antagonists is expected to produce additive inhibition. 
Thus, the lack of additive inhibition may indicate that they were acting on the same 
receptors, probably the NKi receptors that were already surmounted by SR140333. 
Therefore, the present of SR48968 could not produce further blockage. A finding 
that lends support to this hypothesis is that high concentrations of SR48968 
(IC5o=227nM) exhibited significant binding to NKi receptors of the guinea-pig lung 
in vitro (Kudlacz et al., 1993). 
Unfortunately, the above hypothesis could not explain the present observation that 
co-administration of the two antagonists often produced less inhibition than that 
produced by either of the two antagonists administered alone. To account for this 
phenomenon, it is suspected that physical interaction between the two antagonists 
may have taken place when they were co-administered. The molecule of SRI40333 
bears a positively charge quaternary ammonium ion, whereas, SR48968 has 
negatively charged oxygen and chloride atoms. These opposite charges on the two 
antagonists may cause them to attract and adhere to each other. As a result, their 
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binding affinities to the tachykinin receptors will be hindered, and thereby 
diminishing their receptor blocking activities. This suspected interaction may be 
avoidable if the time of administration of the two antagonists was separated. 
Such physical interaction still could not explain the accelerated onset of cartilage and 
bond degradation in the FCA-treated knee in the presence of SRI 40333 and 
SR48968. It is speculated that two mechanisms may be involved here: (1) high doses 
of the two antagonists have direct pro-inflammatory actions, and (2) tachykinin 
receptors mediate both pro- and anti-inflammatory actions, and the latter action is 
affected only by high doses of the tachykinin receptor antagonists. The finding in 
Figure 6.2 (chapter 6), which showed that 1.2mg/kg but not 2.4 mg/kg SR140333 
inhibited joint swelling in the FCA-treated knee lends support to these ideas, but 
further work would be required to consolidate these hypotheses. 
6.5 Conclusions 
The present study demonstrated that tachykinin receptor antagonists are useful agents 
in curtailing the development of FCA-induced arthritis in the rat. This confirmed our 
previous findings that SP is an important mediator of the disease. Of the different 
tachykinin receptor antagonists tested, SR140333 was the most efficacious and it 
showed suppressive action on all the arthritis symptoms. These findings indicate that 
SP contributes to the arthritis process by activiting predominantly the NKi receptors. 
Hence, NKi receptor antagonists may represent potential anti-arthritic drugs. 
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Chapter 7 
Individual and combined effects of dexamethasone and tachykinin 
receptor antagonists on FCA-induced arthritis 
7.1 Introduction 
Glucocorticoids are the most potent and effective agents in controlling chronic 
inflammatory diseases. They exert their effects by binding to a cytoplasmic receptor 
within target cells. Activation of glucocorticoid receptors results in increased or 
decreased transcription of a number of genes involved in the inflammatory process 
(Beato, 1989). Of particular importance is the repression of cytokine gene 
transcription and the direct interaction between the glucocorticoid receptor and other 
transcription factors activated in chronic inflammation (Schule & Evans, 1991). 
Glucocorticoids induce the formation of lipocortin-1 in rat and human leukocytes 
(Peers et al., 1993), which has an inhibitory effect on phospholipase A2 (PLA2), and 
therefore may inhibit the production of lipid mediators, such as leukotrienes, 
prostaglandins and platelet-activating factor. Exposure of rats to endotoxin results in 
inducible nitro oxide synthase (NOS) gene expression that is prevented by prior 
treatment with dexamethasone, which suggests that steroids have an inhibitory effect 
on the inducible NOS gene. The expression of many adhesion molecules on 
endothelial cells is induced by cytokines, and steroids may lead indirectly to a 
reduced expression via their inhibitory effects on cytokines, such as IL-ip and TNFa. 
They may also have a direct inhibitory effect on the expression of adhesion 
molecules such as ICAM-1 and E-selectin; the latter at the level of gene transcription 
(Cronstein et al, 1992). 
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Steroids exert a number of other anti-inflammatory effects that are not yet understood 
at a molecular level. They have an inhibitory effect on plasma exudation from 
postcapillary venules at inflammatory sites. The onset of effect is delayed, suggesting 
that gene transcription and protein synthesis are involved (Camuccio et al., 1987). 
Steroids also markedly reduce the survival of certain inflammatory cells, such as 
eosinophils (Wallen et al., 1991). 
Most patients with chronic inflammatory conditions respond to steroid, but there is a 
small minority of patients who appear to be resistant to steroid therapy. This is most 
clearly documented in asthma but is also seen in patients with other inflammatory or 
immune diseases that require steroids for control, including rheumatoid arthritis, 
systemic lupus erythematosis and transplant rejection. In some patients with 
steroid-resistant arthritis, an increase in lipocortin-1 antibodies has been described 
(Goulding et al., 1989) but this is not found in patients with steroid-resistant asthma 
(Wilkinson et al, 1990). 
Although steroids have potent anti-inflammatory activities that benefits arthritis 
patients, but the doses of steroid required to maintain adequate symptoms relief on a 
long-term basis are accompanied by a high level of side effects. Moreover, it remains 
uncertain to what extent they possess the disease modifying properties of the slow 
acting anti-rheumatic drugs. Indications for their use are therefore restricted and a 
slow acting anti-rheumatoid agent is usually commenced simultaneously with a view 
to gradual withdrawal of steroid therapy when remission has been obtained. Such 
approach is far from ideal because slow acting anti-rheumatoid drugs are not free 
from severe side effects. 
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In the work of the previous chapter, tachykinin receptor antagonists were shown to 
possess promising anti-arthritic activity. This raises the possibility that combined 
administration of steroid with tachykinin receptor antagonist may be a useful strategy 
for the treatment of arthritis. Therefore, in this part of the study, the anti-arthritic 
efficacy of dexamethasone on the rat arthritis model was tested alone and also in 
combination with tachykinin receptor antagonists. 
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12 Method 
Sprague-Dawley rats of 250-300g were anaesthetized with 40mg/kg thiopentone for 
induction of arthritis by FCA as described in Chapter 3. Starting from the day of 
arthritis induction, each of the animals received daily intraperitoneal injection of 
SR140333 (1.2mg/kg); SR48968 (1.2mg/kg); dexamethasone (5mg/kg); 
dexamethasone (1 mg/kg); dexamethasone (1 mg/kg) plus SR140333 (1.2mg/kg), or 
dexamethasone (1 mg/kg) plus SR48968 (1.2mg/kg). On day 1 and day 3 post 
arthritis induction, the rat knee joints were assessed for Evans blue extravasation, 
joint swelling, immune cell accumulation, synovial tissue proliferation and cartilage 
degradation as described previously in chapter 3. 
In another group of animals, arthritis symptoms were assessed on day 7 after arthritis 
induction. The protocol for drug treatments was essentially the same as above, except 
that injection with 5mg/kg dexamethasone were not tested (due to high mortality), 
and injections involving Img/kg dexamethasone were not given daily, but were 
administered on days 0, 3 and 6 instead. 
The body weights of each animal were determined prior to induction and on the day 
of assessment of the arthritis symptoms. 
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7 3 Results 
7,31 Evans blue extravasation 
Compared with saline injections, individual intraperitoneal administration of 
1.2mg/kg/day of the NKi receptor antagonist SR140333, the NK2 receptor antagonist 
SR48968 and Img/kg/day (or every 3 days for 7 days) dexamethasone (DEX) all 
suppressed Evans blue extravasation (n=4-6; P<0.001;尸<0.01; P<0.01, respectively). 
Co-administration of dexamethasone with SR48968 also reduced Evans blue 
extravasation (n-4-6;尸<0.01; two factor ANOVA), but this was not significant to 
that produced by SR48968 alone. Co-administration of dexamehtasone and 
SRI 40333 did not suppress Evans blue extravasation as well as that produced by 
SR140333 alone (P<0.05;尸<0.01, respectively; two factor ANOVA). These results 
are shown in Figures 7.1 and 7.2. 
7.32 Knee joint size 
Compared with saline injections, individual intraperitoneal administration of 
1.2mg/kg/day of SR140333, SR48968 and Img/kg/day (or every 3 days for 7 days) 
dexamethasone all suppressed joint swelling (n二 13-20, P<0.05, P<0.01 and 尸<0.001, 
respectively; two factor ANOVA). Co-administration of dexamethasone with 
SR140333 or SR48968 also reduced the joint swelling (n二 12-27;户<0.001 for both; 
two factor ANOVA), but the inhibitions were not significantly different to those 
produced by the antagonists on their own (尸>0.05; two factor ANOVA). These 
results are shown in Figures 7.3 and Figure 7.4. 
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7.33 Body weight 
Compared with saline injections, individual intraperitoneal administration of 
1.2mg/kg/day of SR140333 and SR48968 had no effect on body weight of the animal 
(n=4-6; P>0.05 for both; Student unpaired �tes t ) , but 5mg/kg/day dexamethasone 
reduced the body weight on day 1 and day 3 post induction of arthritis (n=10-19; 
P<0.001 for both; Student's impaired Mest). Dexamethasone at a dose of Img/kg/day 
administered alone or in combination with SR140333 or SR48968 also significantly 
reduced the rat body weight on day 3 (n=18-19; P<0.001 for all; Student's unpaired 
Mest). The results are shown in Figure 7.5. 
7.34 Cellular infiltration 
Compared with saline injections, individual intraperitoneal administration of 
1.2mg/kg/day of SRI40333 and Img/kg/day (or every 3 days for 7 days) 
dexamethasone both suppressed immune cell accumulation in the infra-petella fat 
pads of the arthritic rat knee joints (n=3;尸<0.05, P<0.05, P<0.001, respectively; two 
factor ANOVA; Figures 7.6 and 7.7). Co-administration of dexamethasone with 
SR140333 produced greater suppression than dexmethasone or SR1403333 alone 
(n二3; P<0.001 for both; two factor ANOVA). However, administration of SR48968 
alone or in combination of dexamethasone had no effect on immune cell 
accumulation (n=3，户>0.05; two factor ANOVA). The results are shown in Figures 
7.6 and 7.8. 
7.35 Synovial tissue proliferation 
Compared with saline injections, individual intraperitoneal administration of 
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1.2mg/kg/day of SR140333 and SR48968, as well as co-administration of 
dexamethasone (or 3 days every 7 days) plus SR48968 had no effect on growth of 
synovial tissue proliferation of the arthritic rat knees. On the other hand, 
dexamethasone administered alone or in combination with SRI 40333 significantly 
reduced the growth (n=3;尸<0.01, P<0.05, respectively; two factor ANOVA). The 
suppression by dexamethasone alone was less than that produced by 
co-administration of dexamethasone and SR140333 (n=3; P<0.01 and 尸<0.001, 
respectively; two factor ANOVA). These results are shown in Figures 7.9, 7.10 and 
7.11. 
7.36 Cartilage degradation 
Compared with saline injections, individual intraperitoneal administration of 
1.2mg/kg/day of SR140333, SR48968 and Img/kg/day (or every 3 days for 7 days) 
dexamethasone all had no effect on cartilage degradation up to 7 days post injection 
of FCA (n=3;尸>0.05 for all; two factor ANOVA). Similarly, co-administration of 
dexamethasone with SR140333 or SR48968 produced no change (n=3; P>0.05 for 
all; two factor ANOVA). These results are shown in Figures 7.12, 7.13 and 7.14. 
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Figure 7.1 
Individual and co-administration of dexamethasone (Img/kg) and SR140333 
(1.2mg/kg/day) on Evans blue extravasation in FCA-induced arthritic rat knee joints. 
Compared with saline injections, individual administration of the NKi receptor 
antagonist SRI40333 (NKi) and dexamethasone (DEX) both suppressed Evans blue 
extravasation (n=4-6; ***尸<0.001; **P<0.01, respectively; two factor ANOVA). 
These suppressions were most obvious on day 1 and day 7 (#P<0.05 - ###尸<0.001; 
Planned Contrasts). Co-administration of dexamethasone with SR140333 (DEXNKi) 
produced no reduction on Evans blue extravasation (n=5-ll;尸>0.05; two factor 
ANOVA), except on day 3 (##P<0.01; Planned Contrasts), this treatment had higher 
Evans blue extravasation than those of control. Data are shown as means士s.e.mean 
(shown by vertical bars) of differences between FCA-injected and contralateral 
saline-injected knees in their amount of Evans blue extravasated in \xglg tissue. 
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Figure 7.2 
Individual and co-administration of dexamethasone (Img/kg) and SR48968 
(1.2mg/kg/day) on Evans blue extravasation in FCA-induced arthritic rat knee joints. 
Compared with saline injections, individual administration of the NK2 receptor 
antagonist SR48968 (NK2) or dexamethasone (DEX), or co-administration of the two 
(DEXNK2) suppressed Evans blue extravasation (n=4-6; **尸<0.01; two factor 
ANOVA). These suppressions were most obvious on day 1 and also on day 7 for 
DEXNKi (#P<0.05; Planned Contrasts). The level of suppression was the same for 
all groups (n=5-6; P>0.05; two factor ANOVA). Data are shown as means士s.e.mean 
(shown by vertical bars) of differences between FCA-injected and contralateral 
saline-injected knees in their amount of Evans blue extravasation in [ig/g tissue. 
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Figure 7.3 
Individual and co-administration of dexamethasone (Img/kg) and SR140333 
(1.2mg/kg/day) on joint swelling in FCA-induced arthritic rat knee joints. Compared 
with saline injections, individual administration of the NKi receptor antagonist 
SR140333 (NKi) or dexamethasone (DEX) or co-administration of the two 
(DEXNKi) suppressed joint swelling (n=12-24; V<0.05 - ***尸<0.001; two factor 
ANOVA). The suppressions were obvious throughout the 7 days for DEX and 
DEXNKi (#P<0.05, ##P<0.01; Planned Contrasts), and on day 1 for NKi (#P<0.05; 
Planned Contrasts). Suppressions produced by DEX and DEXNKi were the same 
(P>0.05; two factor ANOVA). Data are shown as means士s.e.mean (shown by 
vertical bars) of differences between joint sizes of FCA-injected and contralateral 
saline-injected knees in mm. 
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Figure 7,4 
Individual and co-administration of dexamethasone (Img/kg) and SR48968 
(1.2mg/kg/day) on joint swelling in FCA-induced arthritic rat knee joints. Compared 
with saline injections, individual administration of the NK2 receptor antagonist 
SR48968 (NKi) or dexamethasone (DEX) or co-administration of the two (DEXNK2) 
suppressed joint swelling (n=12-27; **P<0.01 _ ***P<0.001; two factor ANOVA). 
These suppressions were obvious throughout the 7 days for DEX and DEXNK2 
(#P>0.05 - ###P<0.001; Planned Contrasts) but only on day 3 for NK2 (#P<0.05; 
Planned Contrasts). Suppressions produced by DEX and DEXNK2 were the same 
(P>0.05; two factor ANOVA). Data are shown as means士s.e.mean (shown by 
vertical bars) of differences between joint sizes of FCA-injected and contralateral 
saline-injected knees in mm. 
173 
A 
in 40-1 o 
？ 20-(0 
O ro 0 - Wr-fi-fifiirti-1'Hr丨 r• I I I I | I [ I I I 丨 
"d) -20" I 
• -40- *** 
•60 J — 





0- [： ^ I 1 
o) - 2 0 -
o I , I 
> 氺氺* *氺氺 **氺 *氺* 
gQ J  
_ S NKi NK2 1DEX 5DEX DEXNK! DEXNK2 
c 
« 40-1 — — , — 
L t • • • Q • ^ 
o TO 0 -
- 2 0 -
'0 
乡 -40-
gA J  
s NKi NK2 1DEX DEXNK1 DEXNK2 
Figure 7.5 
Individual and co-administration of dexamethasone (Img/kg/day; IDEX and 
5mg/kg/day; 5DEX) and tachykinin receptor antagonists (1.2mg/kg/day) on rat body 
weight at (A) day 1, (B) day 3 and (C) day 7 post induction of arthritis by FCA. 
Compared with saline injection (S; n=24-27), 5DEX produced significant reduction 
on the rat body weight at day 1 and day 3 post induction of arthritis (n=16-19; 
***P<0.001; Student's unpaired Mest). IDEX (n二 18) administered alone or in 
combination with SR140333 (DEXNKi； n=19) or SR48968 (DEXNK2； n=18) also 
significantly reduced the rat body weight at day 3 (*** P<0.001; Student's unpaired 
Mest). Data are shown as means士s.e.mean (shown by vertical bars) of differences 
between body weights (g) of each rat prior to induction or arthritis and on the 
specified assessment day after induction. 
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Figure 7.6 
Individual and co-administration of dexamethasone (DEX; Img/kg/dose) and 
tachykinin receptor antagonists (NKi； NK2； 1.2mg/kg/day) on immune cell 
accumulation in the infrapatella fat pads of rat knee joints injected with FCA. 
Immune cell accumulation was less pronounce in DEXNKi treated animals. 
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Figure 7.7 
Individual and co-administration of dexamethasone (Img/kg; DEX) and SR140333 
(1.2mg/kg/day) on immune cell accumulation in the infra-patella fat pads of rat knee 
joints injected with FCA. Compared with saline injections, individual administration 
of the NKi receptor antagonist SR140333 (NKi) or dexamethasone (DEX) or 
co-administration of the two (DEXNKi) suppressed immune cell accumulation (n=3; 
*p<0.05 - ***尸<0.001; two factor ANOVA). The suppression by DEXNKi was most 
obvious on day 3 and day 7 (##P<0.01; Planned Contrasts), while that for DEX was 
most obvious on day 7 (#P<0.05; Planned Contrasts). DEXNKi produced greater 
suppression than DEX or SR140333 administered alone (n=3; ***P<0.001; two 
factor ANOVA). Data are shown as means士s.e.mean (shown by vertical bars) of 
level of immune cell accumulation graded by the criteria described in 
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Figure 7.8 
Individual and co-administration of dexamethasone (Img/kg; DEX) and SR48968 
(1.2mg/kg/day) on immune cell accumulation in the infrapatella fat pads of rat knee 
joints injected with FCA. Compared with saline injections, individual administration 
of the NK2 receptor antagonist SR48968 (NK2) or dexamethasone or 
co-administration of the two (DEXNK2) did not suppress immune cell accumulation 
(n=3; P>0.05; two factor ANOVA), except for DEX on day 7 (#P<0.05; Planned 
Contrasts). Data are shown as means士s.e.mean (shown by vertical bars) of level of 
immune cell accumulation graded by the criteria described in "Methodology" section 
in chapter 3. 177 
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Figure 7.9 
Individual and co-administration of dexamethasone (DEX; Img/kg/day) and 
tachykinin receptor antagonists (NKi;NK21.2mg/kg/day) on growth of synovial tissue 
on menisci of rat knee joints injected with FCA. Synovial tissue growth was minimal 
in the DEXNKi treated animals. 
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Figure 7.10 
Individual and co-administration of dexamethasone (Img/kg; DEX) and SR140333 
(1.2mg/kg/day) on synovial tissue proliferation of rat knee joints injected with FCA. 
Compared with saline injections, administration of NKi receptor antagonist 
SR140333 (NKi) had no effect on synovial tissue proliferation (n=3; P>0.05 for both; 
two factor ANOVA). Administration of dexamethasone alone (DEX) or 
co-administered with SR140333 (DEXNKi) both suppressed synovial tissue 
proliferation (n=3; **P<0.01; ***P<0.001, respectively; two factor ANOVA). 
DEXNKi treatment produced greater suppression than that of DEX or NKi (n=3; 
**P<0.01; ***P<0.001, respectively; two factor ANOVA). The suppression by DEX 
treatment was most obvious on day 7 while suppression by DEXNKi was more 
obvious from day 3 onwards (#P<0.05; ##P<0.01; Planned Contrasts). Data are 
shown as means士s.e.mean (shown by vertical bars) of level of synovial tissue 
proliferation graded by the criteria described in "Methodology" section in chapter 3. 
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Figure 7.11 
Individual and co-administration of dexamethasone (Img/kg; DEX) and SR48968 
(1.2mg/kg/day) on synovial tissue proliferation of rat knee joints injected with FCA. 
Compared with saline injections, individual administration of the NKi receptor 
antagonist SR48968 (NK2) or co-administration of the antagonist with 
dexamethasone (DEXNKi) both had no effect on synovial tissue proliferation (n=3; 
尸>0.05; two factor ANOVA). However, administration of dexamethasone alone 
(DEX) suppressed synovial tissue proliferation (n=3; *P<0.05; two factor ANOVA) 
and the suppression was most obvious on day 7 (#P<0.05; Planned Contrasts). Data 
are shown as means士s.e.mean (shown by vertical bars) of level of synovial tissue 
proliferation graded by the criteria described in "Methodology" section in chapter 3. 
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Figure 7.12 
Individual and co-administrations of dexamethasone (DEX; Img/kg/dose) and 
tachykinin receptor antagonists (NKi； NK21.2mg/kg/day) on cartilage degradation 
in rat knee joints injected with FCA. None of the drug treatment affected the pattern 
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Figure 7.13 
Individual administration of NKi receptor antagonist SR140333 (NKi), 
dexamethasone (DEX; Img/kg/day), and co-administration of the two (DEXNKi) on 
cartilage degradation in rat knee joints injected with FCA. Compared with saline 
injections, none of the drug treatments affected the pattern of cartilage degradation 
(n=3; F>0.05; two factor ANOVA). Data are shown as means±s.e.mean (shown by 
vertical bars) of level of cartilage degradation graded by the criteria described in 
"Methodology" section in chapter 3. 
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Figure 7.14 
Individual administration of the NK2 receptor antagonist SR48968 (NK2), 
dexamethasone (DEX, Img/kg/day), and co-administration of the two (DEXNK2) on 
cartilage degradation in rat knee joints injected with FCA. Compared with saline 
injections, none of the drug treatment affected the pattern of cartilage degradation 
(n=3; P>0.05; two factor ANOVA). Data are shown as means士s.e.mean (shown by 
vertical bars) of level of cartilage degradation graded by the criteria described in 
"Methodology" section in chapter 3. 
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7.4 Discussion 
The present study showed that intraperitoneal administration of dexamethasone 
produced significant suppression on all symptoms of the arthritis, except it had no 
effect on cartilage degradation up to day 7. This is in line with the general consensus 
that steroids provide symptomatic relief for arthritis patients, but they do not alter the 
course of the disease. Waltraud and Judith (1998) showed that 5mg/kg asimadoline 
(an opioid agonist) significantly reduced the severity of adjuvant-induced arthritis in 
the rat without any complication. However, the present study showed that the use of 
high dose dexamethasone has two significant drawbacks (1) the animals suffered 
severe weight loss during dexamethasone treatment (Img/kg/day or 5mg/kg/day), 
and (2) the mortality rate was more than 50% when dexamethasone was given at a 
dose of lmg/kg/3days for 2 weeks. This has restricted the dose and frequency of 
administration of the steroid in the present study. Toxicities of dexamethasone 
include disturbance of water and electrolyte balance, hyperglycaemia, muscle 
weakness, osteopososis, hypertension and increase chances of opportunistic infection 
(as mentioned in section of “introduction，，). All these side-effects could contribute to 
the weight loss and the high mortality rate. 
As discuss earlier, it is likely that the most important anti-inflammatory effects of 
steroids involve repression of gene for cytokines and lipid mediator enzymes. 
Nevertheless, it should not be overlooked that steroids increase expression of several 
enzymes, e.g. angiotensin converting enzyme and neutral endopeptidase (NEP), that 
degrade mediators such as bradykinin and SP (Borson & Gmenert, 1991; 
Mendelsohn et al, 1982). The latter enzyme is of particular important in degrading 
tachykinins released from sensory nerves. Steroids also decrease the transcription of 
the gene coding for tachykinin NKi receptor via an interaction with other 
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transcription factors (Adcock et al, 1993; Ihara & Nakanishi, 1990). These findings 
indicate that the indirect actions of steroid may inhibit the inflammatory effects of SP 
mediated by NKi receptors. Furthermore, steroids may reduce the active 
concentrations of SP in tissues. It is therefore suspected that part of the 
anti-inflammatory effects of steroids is attributed to suppression of neurogenic 
inflammation. 
The present study showed that co-administration of dexamethasone with the NKi 
receptor antagonist SRI40333 produced no additive or synergistic inhibition on 
Evans blue extravasation and joint swelling in the arthritic rat knee joints. This is in 
accord with the above speculation that dexamethasone on its own already abolished 
the NKi receptor-mediated effects, and hence the additional NKi receptor blockade 
by the antagonist had made no difference on the degree of inhibition. On the other 
hand, the present study also showed that the inhibition on immune cell infiltration 
and synovial tissue proliferation produced by dexamethasone were more marked in 
the presence of SR140333. The reasons for these discrepant results are unknown. 
Perhaps, unlike Evans blue extravasation and joint swelling, the neurogenic 
contribution to immune cell infiltration and synovial tissue proliferation was not 
abolished by the dosage of dexamethasone used in these experiments. Therefore, in 
the latter case, the blockage of NKi receptors by SR140333 produced further 
inhibition over that exerted by dexamethasone. Higher doses of dexamethasone could 
not be tested in the present study due to the reasons mentioned above. 
Another interesting finding in the present study is that co-administration of 
dexamethasone with the NKi receptor antagonist SR48968 produced no additive or 
synergistic inhibition on all the arthritis symptoms assessed. These findings support 
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the previous conclusion that NK2 receptors are less important (and may be 
insignificant) compared with NKi receptors in mediating the inflammatory effects of 
tachykinins in the present model of arthritis. SR48968 itself has weak anti-arthritic 
actions，but this possibly reflects its low efficacy in inhibiting NKi receptors. 
An unexpected finding is that co-administration of dexamethasone with SR48968 
had augmented immune cell infiltration compared to control. Co-administration of 
dexamethasone with SRI40333 also produced lesser inhibition on Evans blue 
extravasation than that produced by the dexamethasone or SR140333 alone. The 
reason for these unexpected findings is suspected to be the same as that described in 
chapter 6; that high concentrations of the tachykinin receptor antagonists possess 
either direct or indirect pro-inflammatory actions. 
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7.5 Conclusions 
Dexamethasone, the tachykinin NKi receptor antagonist SR140333, and to a lesser 
extend the NKi receptor antagonist SR48968 all possess anti-arthritic efficacies in the 
present rat monoarthritis model. NK2 receptor-mediated effects are possibly 
insignificant, whereas, NKi receptor-mediated effects are of substantial importance. 
Hence, co-administration of dexamethasone and SR140333 produced greater 
suppression on immune cell infiltration and synovial tissue proliferation than those 
produced by either of these agents on their own. These findings suggest that lower 
doses of steroids may be required to control arthritis symptoms when an NKi 
receptor antagonist is concurrently given. Such combination may be useful in 




General discussions and conclusions 
Current therapies for arthritic diseases can provide symptomatic relief for patients, 
but often have no long-term beneficial impact on the course of the disease. This is 
largely due to the fact that multiple inflammatory mediators are involved in the 
manifestation of the disease. Conventional anti-arthritic therapy employs either 
glucocorticoids or NSAIDs that are effective in inhibiting or modulating the actions 
of only some of the mediators that are involved. Often the actions of other mediators 
are not affected and the treatment result is only partial relief of the symptoms. 
It is now recognized that an important group of inflammatory mediators have been 
neglected in current anti-arthritic therapy (Rees et al, 1994). Much evidence 
suggests that the tachykinin SP released from sensory neurones in the joint makes a 
significant contribution to the inflammatory process (for review see Ferrell and Lam, 
1996). Thus, experiments of the present study were designed to investigate the 
importance of SP in the development of chronic arthritis and to examine the use of 
tachykinin receptor antagonists as anti-arthritis agents. In addition, the study tested 
the anti-arthritic efficacies of tachykinin receptor antagonists combined with a 
steroid. 
Since experimental animal models provide the only means of investigating 
conditions that resemble human diseases without the use of human subjects, the first 
objective of the present study was to establish an animal model of chronic arthritis. 
Previously, an animal model of chronic monoarthritis has been developed by 
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unilateral intra-articular administration of a small dose of FCA into knee joints of 
inbred species of rats {Dowed et al., 1998). The present study extended the model to 
outbred Sprague-Dawley rats and found them to be just as suitable, if not better than 
the use of inbred Lewis rats. This monoarthritis model has many of the 
characteristics of the human disease such as hyperaemia, increased vascular 
permeability, joint swelling, immune cell infiltration, synovial tissue proliferation, 
cartilage degradation and bone erosion. It is also devoid of systemic complications of 
conventional polyarthritis models. 
Intra-articular administration of SP into arthritic rat knee joints augmented the 
hyperaemia and vascular leakage in these joints. It induced cartilage degradation in 
relatively normal contralteral knees. These findings indicate that exogenously 
applied SP could exacerbate the severity of arthritis, but FCA treatment alone is 
possibly sufficient to elicit peak damage to the cartilage and bone over a long time 
course, without the need of exogenous SP. This finings are not unexpected since SP 
had been repeated shown to possess pro-inflammatory actions such as vasodilatation 
(Lam & Ferrdl, 1993a; 1993b; Lam et al., 1993), increase vascular permeability 
(Lam & Ferrell, 1989; 1990; 1991; Lam et aL, 1993; Scott et aL, 1991; 1992), 
upregulate the expression of adhesion molecules by endothelial cells (Lotz et al, 
1988), act as chemoattractant for immune cells (Eglezos, 1991; Lotz et al, 1988), 
and reduce the synthesis of proteoglycan that could unbalance matrix formation in 
the cartilage leading to tissue degradation (Decaris, 1999). 
A less expected finding is that unilateral intra-articular injection of SP in the arthritic 
rat knees promoted the spread of the arthritis symptoms to the, otherwise, relatively 
normal contralateral knee joints. The half-life of SP in the systemic circulation is 
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short (Scott et al., 1991), and systemic absorption of SP is therefore unlikely to 
account for the contralateral effects. It is more reasonable to assume that SP was 
acting via the "neurogenic switching" mechanism (Meggs, 1995), in such a way that 
it activates nociceptive neurones to trigger impulses to the brain; and some of these 
impulses were relayed at the spinal cord or higher centers of the brain to the 
contralateral side; thus causing the release of neurogenic mediators and produced the 
contralateral arthritis symptoms. In retrospect, it was fortunate that a monoarthritis 
model rather than a conventional polyarthritis model was used for the present study, 
as the contralateral effects of SP will not be identifiable in the latter model. 
Studies with NKi receptor antagonists showed that SR140333 was more potent than 
RP67580, and CP99994 was ineffective in reducing the Evans blue extravasation 
response in the arthritic rats, which agreed with their relative half-life and selectively 
on rat NKi receptors. SRI 40333 reduced vascular changes and all the histological 
changes in the arthritic rat knee joint, whereas, SR48968 reduced vascular changes 
and synovial tissue proliferation only. These findings indicate that NKi receptors are 
of much greater importance than the other tachykinin receptor types for the 
development of chronic arthritis. Hence, co-administration of SR140333 and 
SR48968 was found to produce no bigger suppression of the arthritic symptoms than 
that produced by the NKi receptor antagonist on its own. 
Steroids are powerful anti-inflammatory agents that provide symptomatic relief for 
arthritis patients, but they do not alter the course of the disease. This statement was 
supported by the present findings that showed dexamethasone was effective in 
suppressing all the arthritis symptoms, except cartilage degradation which it had no 
effect. Dexamethasone treatment was associated with drastic weight loss and high 
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mortality rate, and hence could not be given at high dose or for a long period. 
Co-administration of dexamethasone with NKi receptor antagonist SRI 40333 
produced more marked inhibition on immune cell infiltration and synovial tissue 
proliferation than those produced by either of the two drugs on their own. On the 
other hand, co-administration of dexamethasone with the NKi receptor antagonist 
SR48968 produced no additive or synergistic inhibition on all the arthritis symptoms. 
These results, again, confirmed that NKi receptor-mediated effects are of greater 
importance than NKi receptor-mediated effects in the development of the present 
arthritis model. The findings also indicate that NKi receptor antagonist can enhance 
the anti-arthritic efficacies of dexamethasone and vice versa. Hence, it is proposed 
that a low dose of dexamethasone may be combined with an NKi receptor antagonist 
to provide adequate control of the arthritis symptoms. Such combination may be 
useful in reducing steroid toxicities in the treatment of arthritis. 
In conclusion, this study has established an animal model of chronic monoarthritis in 
Sprague-Dawley rats. SP was confirmed to be an important mediator for the 
development of the arthritis, as it was shown to exacerbate, accelerate and promote 
the spreading of the disease. These effects are attributed to the actions of SP on NKi 
receptors. The study also presented evidence that NKi receptor antagonists possess 
anti-arthritic efficacies, and that they may be combined with low dose steroids to 
form a less toxic treatment for the disease. 
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